<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName A++V2.4.dtd?>
<?SourceDTD.Version 2.4?>
<?ConverterInfo.XSLTName springer2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Sci Rep</journal-id>
    <journal-id journal-id-type="iso-abbrev">Sci Rep</journal-id>
    <journal-title-group>
      <journal-title>Scientific Reports</journal-title>
    </journal-title-group>
    <issn pub-type="epub">2045-2322</issn>
    <publisher>
      <publisher-name>Nature Publishing Group UK</publisher-name>
      <publisher-loc>London</publisher-loc>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">9525257</article-id>
    <article-id pub-id-type="publisher-id">20143</article-id>
    <article-id pub-id-type="doi">10.1038/s41598-022-20143-5</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Article</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>StackPR is a new computational approach for large-scale identification of progesterone receptor antagonists using the stacking strategy</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Schaduangrat</surname>
          <given-names>Nalini</given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Anuwongcharoen</surname>
          <given-names>Nuttapat</given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Moni</surname>
          <given-names>Mohammad Ali</given-names>
        </name>
        <xref ref-type="aff" rid="Aff2">2</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Lio’</surname>
          <given-names>Pietro</given-names>
        </name>
        <xref ref-type="aff" rid="Aff3">3</xref>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <name>
          <surname>Charoenkwan</surname>
          <given-names>Phasit</given-names>
        </name>
        <address>
          <email>phasit.c@cmu.ac.th</email>
        </address>
        <xref ref-type="aff" rid="Aff4">4</xref>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <name>
          <surname>Shoombuatong</surname>
          <given-names>Watshara</given-names>
        </name>
        <address>
          <email>watshara.sho@mahidol.ac.th</email>
        </address>
        <xref ref-type="aff" rid="Aff1">1</xref>
      </contrib>
      <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.10223.32</institution-id><institution-id institution-id-type="ISNI">0000 0004 1937 0490</institution-id><institution>Center of Data Mining and Biomedical Informatics, Faculty of Medical Technology, </institution><institution>Mahidol University, </institution></institution-wrap>Bangkok, 10700 Thailand </aff>
      <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.1003.2</institution-id><institution-id institution-id-type="ISNI">0000 0000 9320 7537</institution-id><institution>Artificial Intelligence &amp; Digital Health Data Science, School of Health and Rehabilitation Sciences, Faculty of Health and Behavioural Sciences, </institution><institution>The University of Queensland, </institution></institution-wrap>St Lucia, QLD 4072 Australia </aff>
      <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.5335.0</institution-id><institution-id institution-id-type="ISNI">0000000121885934</institution-id><institution>Department of Computer Science and Technology, </institution><institution>University of Cambridge, </institution></institution-wrap>Cambridge, CB3 0FD UK </aff>
      <aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.7132.7</institution-id><institution-id institution-id-type="ISNI">0000 0000 9039 7662</institution-id><institution>Modern Management and Information Technology, College of Arts, Media and Technology, </institution><institution>Chiang Mai University, </institution></institution-wrap>Chiang Mai, 50200 Thailand </aff>
    </contrib-group>
    <pub-date pub-type="epub">
      <day>30</day>
      <month>9</month>
      <year>2022</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>30</day>
      <month>9</month>
      <year>2022</year>
    </pub-date>
    <pub-date pub-type="collection">
      <year>2022</year>
    </pub-date>
    <volume>12</volume>
    <elocation-id>16435</elocation-id>
    <history>
      <date date-type="received">
        <day>18</day>
        <month>7</month>
        <year>2022</year>
      </date>
      <date date-type="accepted">
        <day>9</day>
        <month>9</month>
        <year>2022</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2022</copyright-statement>
      <license>
        <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p>
      </license>
    </permissions>
    <abstract id="Abs1">
      <p id="Par1">Progesterone receptors (PRs) are implicated in various cancers since their presence/absence can determine clinical outcomes. The overstimulation of progesterone can facilitate oncogenesis and thus, its modulation through PR inhibition is urgently needed. To address this issue, a novel stacked ensemble learning approach (termed StackPR) is presented for fast, accurate, and large-scale identification of PR antagonists using only SMILES notation without the need for 3D structural information. We employed six popular machine learning (ML) algorithms (i.e., logistic regression, partial least squares, k-nearest neighbor, support vector machine, extremely randomized trees, and random forest) coupled with twelve conventional molecular descriptors to create 72 baseline models. Then, a genetic algorithm in conjunction with the self-assessment-report approach was utilized to determine <italic>m</italic> out of the 72 baseline models as means of developing the final meta-predictor using the stacking strategy and tenfold cross-validation test. Experimental results on the independent test dataset show that StackPR achieved impressive predictive performance with an accuracy of 0.966 and Matthew’s coefficient correlation of 0.925. In addition, analysis based on the SHapley Additive exPlanation algorithm and molecular docking indicates that aliphatic hydrocarbons and nitrogen-containing substructures were the most important features for having PR antagonist activity. Finally, we implemented an online webserver using StackPR, which is freely accessible at <ext-link ext-link-type="uri" xlink:href="http://pmlabstack.pythonanywhere.com/StackPR">http://pmlabstack.pythonanywhere.com/StackPR</ext-link>. StackPR is anticipated to be a powerful computational tool for the large-scale identification of unknown PR antagonist candidates for follow-up experimental validation.</p>
    </abstract>
    <kwd-group kwd-group-type="npg-subject">
      <title>Subject terms</title>
      <kwd>Data mining</kwd>
      <kwd>Machine learning</kwd>
      <kwd>Cheminformatics</kwd>
    </kwd-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution>Mahidol University</institution>
        </funding-source>
      </award-group>
    </funding-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution>Chiang Mai</institution>
        </funding-source>
      </award-group>
    </funding-group>
    <custom-meta-group>
      <custom-meta>
        <meta-name>issue-copyright-statement</meta-name>
        <meta-value>© The Author(s) 2022</meta-value>
      </custom-meta>
    </custom-meta-group>
  </article-meta>
</front>
<body>
  <sec id="Sec1">
    <title>Introduction</title>
    <p id="Par2">Progesterone receptor (PR) has emerged as a potential therapeutic target due to its increasingly recognized role in cancer development and progression. PR is implicated in various cancers such as breast and gynecological cancers (i.e., endometrial and ovarian cancers). However, their most studied implications lie in breast cancer. Cancer is still a major public health concern worldwide, with breast cancer ranking as the most commonly occurring in women. As of 2020, an estimated 2.3 million women were diagnosed with breast cancer resulting in 685,000 deaths globally<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>. In addition, ovarian and endometrial cancers ranked sixth and eighth out of the top ten cancers in women with incidence rates of 313,959 and 417,367, respectively<sup><xref ref-type="bibr" rid="CR2">2</xref></sup>. Furthermore, according to the presence or absence of Estrogen receptor (ER) and PR, as well as human epidermal growth factor receptor 2 (Her2), breast cancer can be defined into 3 major groups. These include ER/PR-positive/Her2-negative tumors occurring in approximately 70% of patients, Her2 positive tumors in 15–20% of patients, and triple-negative tumors that lack all receptors in 15% of patients<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>.</p>
    <p id="Par3">PR belongs to the steroid nuclear receptor family which consists of other members such as ER, androgen receptor (AR), glucocorticoid receptor (GR), and mineralocorticoid receptor (MR). The role of PR in breast cancer through ER modulation has been investigated and as such, the expression of PR can estimate breast cancer prognosis<sup><xref ref-type="bibr" rid="CR4">4</xref>,<xref ref-type="bibr" rid="CR5">5</xref></sup>. Progesterone, the female sex hormone and endogenous ligand for PR, is involved in the development of the mammary glands, in the maintenance of pregnancy, and in the female menstrual cycle<sup><xref ref-type="bibr" rid="CR6">6</xref>,<xref ref-type="bibr" rid="CR7">7</xref></sup>. In the last decade, extensive research using murine models has recognized the role of progesterone in the development of breast cancer<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>. Additionally, these studies indicate that progesterone along with estrogen is a significant hormone involved in mammary gland development<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>. Triggered by estrogen, progesterone stimulates the growth of murine mammary stem cells (MSC) and inherently promotes the regeneration of the mammary gland<sup><xref ref-type="bibr" rid="CR10">10</xref></sup>. Subsequently, breast cancer risk is amplified due to the increase in MSC numbers in response to progesterone<sup><xref ref-type="bibr" rid="CR11">11</xref>,<xref ref-type="bibr" rid="CR12">12</xref></sup>. This facilitates oncogenesis through the accumulation of replication mutations<sup><xref ref-type="bibr" rid="CR13">13</xref>,<xref ref-type="bibr" rid="CR14">14</xref></sup>. Therefore, modulation of progesterone through PR inhibition is vital for decreasing MSC and thus, slowing accumulation.</p>
    <p id="Par4">As stated above, breast cancer cells need estrogen and progesterone to grow hence, creating ER/PR positive or negative tumors. Determining the hormone response status of a tumor is the gold standard method and is crucial for patients to suitably benefit from endocrine therapy. Endocrine therapy used for hormone-positive breast cancer patients constitutes an easy-to-approach option for patients as it is generally well tolerated. However, A cohort study conducted on patients with breast cancer indicated that those with ER-positive/PR-negative tumors had a lower survival rate than those with ER-positive/PR-positive tumors<sup><xref ref-type="bibr" rid="CR15">15</xref>,<xref ref-type="bibr" rid="CR16">16</xref></sup>. This study suggests that, despite being ER-positive, the loss of PR is associated with the development of resistance in such tumors<sup><xref ref-type="bibr" rid="CR17">17</xref></sup>. Thus, the research and development of PR-targeted compounds offer a great opportunity.</p>
    <p id="Par5">The lack of specificity regarding PR-targeting drugs exhibits a significant barrier in the clinical translation of PR-targeted therapies. Until now, the use of steroidal PR agonists has been mainly in the areas of oral contraception and postmenopausal hormone therapy<sup><xref ref-type="bibr" rid="CR18">18</xref>–<xref ref-type="bibr" rid="CR20">20</xref></sup>. However, the in vitro cell growth inhibitory effects afforded by PR antagonists particularly in ovarian, breast, prostate, and bone cancer cells, are now garnering attention as a potential anti-cancer regimen<sup><xref ref-type="bibr" rid="CR21">21</xref>–<xref ref-type="bibr" rid="CR25">25</xref></sup>. Furthermore, despite high in vitro antagonist activity against PR, recent clinical trials with mifepristone, a selective progesterone receptor modulator (SPRM), have largely been unsuccessful for ovarian cancer<sup><xref ref-type="bibr" rid="CR23">23</xref>,<xref ref-type="bibr" rid="CR26">26</xref></sup>. Despite achieving substantial activity to counter breast cancer in clinical trials, SPRMs have not been well endured by most participants due to their great affinity and responsiveness to GR<sup><xref ref-type="bibr" rid="CR24">24</xref></sup>. Recently, interest in SPRMs for the treatment of breast cancer has been revived due to the discovery of potent progesterone antagonists having minimal antiglucocorticoid activity, such as telapristone acetate (TPA) and ulipristal acetate (UPA). TPA and UPA are currently in phase II and phase III clinical trials for treating endometriosis and breast cancer, and abnormal uterine bleeding, respectively<sup><xref ref-type="bibr" rid="CR19">19</xref>,<xref ref-type="bibr" rid="CR27">27</xref>–<xref ref-type="bibr" rid="CR29">29</xref></sup>. Vilaprisan is another SPRM that underwent efficacy and safety assessment in phase III clinical trials of the oral treatment for uterine fibroids<sup><xref ref-type="bibr" rid="CR30">30</xref></sup>. However, reports of hepato-cytotoxicity by SPRMs in other clinical trials halted the aforementioned one<sup><xref ref-type="bibr" rid="CR31">31</xref></sup>. Similarly, concerns regarding hepato-cytotoxicity have limited the advancement of onipristone, a full progesterone antagonist, despite promising activity against breast and gynecological cancers. The clinical trial with onipristone is currently being re-evaluated with a lower drug dosage<sup><xref ref-type="bibr" rid="CR32">32</xref></sup>. In this regard, there appears to be particular promise in developing newer PR antagonists.</p>
    <p id="Par6">The conventional process of novel drug discovery represents a costly, labor-, and time-intensive venture. These days, the use of computer-aided drug discovery methods has increasingly played essential and fundamental roles as part of the drug discovery process to alleviate the burden of labor and expense. As such, over the past decade, several computational approaches (i.e., molecular docking, quantitative structure–activity relationship (QSAR), and deep-learning) have been utilized for the exploration of PR modulators pertaining to 3D QSAR and docking studies of steroidal<sup><xref ref-type="bibr" rid="CR33">33</xref></sup> and non-steroidal<sup><xref ref-type="bibr" rid="CR34">34</xref>–<xref ref-type="bibr" rid="CR37">37</xref></sup> analogs and, more recently, deep learning-based QSAR<sup><xref ref-type="bibr" rid="CR38">38</xref></sup>. However, all these approaches might be limited in the quick and accurate identification of new PR antagonists from large-scale uncharacterized compounds. On the other hand, machine learning (ML) methods can utilize only SMILES information without the need for 3D structural information, highlighting their great efficiency in the large-scale identification of compounds.</p>
    <p id="Par7">Thus, in this study, we developed StackPR, a novel and stacked computational model for accurate and large-scale identification of compounds against PR by using only SMILES notation without the use of 3D structural information. Firstly, we comprehensively investigated the impact of different molecular descriptors and ML algorithms in the identification of PR antagonists by utilizing six popular ML algorithms (i.e., logistic regression (LR), partial least squares (PLS), k-nearest neighbor (KNN), support vector machine (SVM), extremely randomized trees (ET) and random forest (RF)) coupled with twelve conventional molecular descriptors. Secondly, a total of 72 different classifiers were developed and considered as baseline models. Then, a genetic algorithm cooperating with the self-assessment-report approach (GA-SAR) algorithm was employed to determine <italic>m</italic> out of the 72 baseline models for constructing the optimal meta-predictor using the stacking strategy. Thirdly, the SHapley Additive exPlanations (SHAP) algorithm was used to indicate the most important features for StackPR. Finally, molecular docking was conducted to determine the top compounds having a high binding affinity towards PR. The top-scoring compound was then further analyzed for its binding interactions and substructures.</p>
  </sec>
  <sec id="Sec2">
    <title>Materials and methods</title>
    <sec id="Sec3">
      <title>Dataset construction</title>
      <p id="Par8">The dataset used in this study was collected from the ChEMBL database (Target ID: CHEMBL208; version 25)<sup><xref ref-type="bibr" rid="CR39">39</xref></sup>, which consisted of an initial set of 5,240 compounds with activity for PR. After the data curation process, a final data set of 1,168 compounds were obtained using IC<sub>50</sub> (half-maximal inhibitory concentration) as the bioactivity unit for further investigation. IC<sub>50</sub> denotes the amount of drug required for the inhibition of a biological process by half, thus stipulating the potency measure of an antagonist drug in pharmacological research<sup><xref ref-type="bibr" rid="CR40">40</xref></sup>. Furthermore, Beck et al.<sup><xref ref-type="bibr" rid="CR41">41</xref></sup> reports that IC<sub>50</sub> can be used effectively in building robust and reliable models to support SAR (structure–activity relationship) studies in drug discovery. Bioactivity thresholds of IC<sub>50</sub> ≤ 1 μM and ≥ 10 μM were applied to the final data set of 1,168 to separate compounds into active and inactive groups, respectively. Compounds with biological activity IC<sub>50</sub> values ranging between 1 and 10 μM (i.e., intermediate compounds), which consisted of 445 compounds, were not selected for this study. As a result, a high-quality dataset was obtained which consisted of 463 active (positive samples) and 260 (negative samples) inactive compounds. Of these compounds, 370 active and 208 inactive compounds are considered as the training dataset (called TRN515), and the remaining compounds (93 active and 52 inactive compounds) are used as the independent test dataset (called IND145).</p>
    </sec>
    <sec id="Sec4">
      <title>Feature engineering</title>
      <p id="Par9">Molecular fingerprints stipulate data regarding the substructures that are inherently present in a molecule and thus, are important in QSAR studies. Using the built-in function of the PADEL-descriptor software, salt was removed and tautomers were standardized during structure pre-processing. Herein, the SMILES notation was used as the input for descriptor calculations. SMILES strings are a useful representation of molecules while gaining the advantages in terms of their storage and handling<sup><xref ref-type="bibr" rid="CR42">42</xref></sup>. We utilized twelve molecular fingerprints, to generate structural features of the investigated compounds. The twelve fingerprints consisted of AP2D, Circle, CKD, CKDExt, CKDGraph, Estate, FP4, FP4C, Hybrid, KR, MACCS, and PubChem. Details of each fingerprint descriptor can be found in Table <xref rid="Tab1" ref-type="table">1</xref>. Herein, all molecular descriptors can be extracted using the Python environment<sup><xref ref-type="bibr" rid="CR43">43</xref></sup>.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Summary of twelve molecular fingerprints used in this study.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Fingerprint</th><th align="left">Abbreviation</th><th align="left">#Feature</th><th align="left">Description</th><th align="left">Ref</th></tr></thead><tbody><tr><td align="left">2D atom pair</td><td align="left">AP2D</td><td align="left">780</td><td align="left">Presence of atom pairs at various topological distances</td><td align="left"><sup><xref ref-type="bibr" rid="CR87">87</xref></sup></td></tr><tr><td align="left">CDK</td><td align="left">CKD</td><td align="left">1024</td><td align="left">Fingerprint of length 1024 and search depth of 8</td><td align="left"><sup><xref ref-type="bibr" rid="CR88">88</xref></sup></td></tr><tr><td align="left">CDK extended</td><td align="left">CKDExt</td><td align="left">1024</td><td align="left">Extends the fingerprint with additional bits describing ring features</td><td align="left"><sup><xref ref-type="bibr" rid="CR88">88</xref></sup></td></tr><tr><td align="left">CDK graph only</td><td align="left">CKDGraph</td><td align="left">1024</td><td align="left">A special version that considers only the connectivity and not bond order</td><td align="left"><sup><xref ref-type="bibr" rid="CR88">88</xref></sup></td></tr><tr><td align="left">Circle</td><td align="left">Circle</td><td align="left">1024</td><td align="left">Circular fingerprint</td><td align="left"><sup><xref ref-type="bibr" rid="CR89">89</xref></sup></td></tr><tr><td align="left">EState</td><td align="left">EState</td><td align="left">79</td><td align="left">Electrotopological state atom types</td><td align="left"><sup><xref ref-type="bibr" rid="CR90">90</xref></sup></td></tr><tr><td align="left">Hybrid</td><td align="left">Hybrid</td><td align="left">1024</td><td align="left">CDK hybridization fingerprint</td><td align="left"><sup><xref ref-type="bibr" rid="CR89">89</xref></sup></td></tr><tr><td align="left">Klekota–Roth</td><td align="left">KR</td><td align="left">4860</td><td align="left">Presence of chemical substructures</td><td align="left"><sup><xref ref-type="bibr" rid="CR91">91</xref></sup></td></tr><tr><td align="left">MACCS</td><td align="left">MACCS</td><td align="left">166</td><td align="left">Binary representation of chemical features defined by MACCS keys</td><td align="left"><sup><xref ref-type="bibr" rid="CR92">92</xref></sup></td></tr><tr><td align="left">Pubchem</td><td align="left">Pubchem</td><td align="left">881</td><td align="left">Binary representation of substructures defined by PubChem</td><td align="left"><sup><xref ref-type="bibr" rid="CR93">93</xref></sup></td></tr><tr><td align="left">Substructure</td><td align="left">FP4</td><td align="left">307</td><td align="left">Presence of SMARTS patterns for functional groups</td><td align="left"><sup><xref ref-type="bibr" rid="CR94">94</xref></sup></td></tr><tr><td align="left">Substructure count</td><td align="left">FP4C</td><td align="left">307</td><td align="left">Count of SMARTS patterns for functional groups</td><td align="left"><sup><xref ref-type="bibr" rid="CR94">94</xref></sup></td></tr></tbody></table></table-wrap></p>
    </sec>
    <sec id="Sec5">
      <title>StackPR framework</title>
      <p id="Par10">In this section, we describe our stacked ensemble learning framework (named StackPR) designed for the high-throughput identification of PR antagonists. Unlike other conventional ensemble strategies, the stacking strategy integrates the strengths of different predictive models without human intervention to generate the final meta-predictor<sup><xref ref-type="bibr" rid="CR44">44</xref>–<xref ref-type="bibr" rid="CR47">47</xref></sup>. To date, numerous previous studies have indicated that the final meta-predictor can potentially attain a more stable predictive performance<sup><xref ref-type="bibr" rid="CR48">48</xref>–<xref ref-type="bibr" rid="CR50">50</xref></sup>. The overall workflow for the development of StackPR contains three major steps (i.e., baseline model construction, new feature vector generation, and meta-predictor development) as provided in the paragraphs hereafter (Fig. <xref rid="Fig1" ref-type="fig">1</xref>).<fig id="Fig1"><label>Figure 1</label><caption><p>System flowchart of the proposed StackPR. The overall workflow for the development of StackPR contains three major steps: dataset construction, baseline model construction and new feature vector generation and meta-predictor development.</p></caption><graphic xlink:href="41598_2022_20143_Fig1_HTML" id="MO1"/></fig></p>
      <p id="Par11">In the first step, we used twelve different molecular descriptors (AP2D, Circle, CKD, CKDExt, CKDGraph, Estate, FP4, FP4C, Hybrid, KR, MACCS, and PubChem) in combination with six ML algorithms (LR, PLS, KNN, SVM, ET, and RF) to generate a collection of baseline models. Specially, all the molecular descriptors were normalized in the range of 0–1, when training the six ML classifiers. As a result, a total of 72 baseline models were created. Herein, we utilized ET, LR, RF, and SVM classifiers with their optimal parameters, where the search range is recorded in Table <xref rid="Tab2" ref-type="table">2</xref>. In the meanwhile, KNN and PLS classifiers were generated by using their default parameters. All the baseline models were built and optimized using the Scikit-learn v0.22.0 package<sup><xref ref-type="bibr" rid="CR51">51</xref></sup> with a tenfold cross-validation test. In addition, we evaluated and analyzed the effect of molecular descriptors and ML classifiers in PR antagonist identification by performing a tenfold cross-validation test to determine the best-performing baseline model in terms of Matthew’s coefficient correlation (MCC). In addition, we evaluated and analyzed the effect of molecular descriptors and ML classifiers in PR antagonist identification by performing a tenfold cross-validation test to determine the best-performing baseline model in terms of Matthew’s coefficient correlation (MCC).<table-wrap id="Tab2"><label>Table 2</label><caption><p>Hyperparameter search details for six different ML classifiers.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Method</th><th align="left">Parameters</th><th align="left">Range of parameters</th></tr></thead><tbody><tr><td align="left">ET</td><td align="left">n_estimators</td><td align="left">[20, 50, 100, 200, 500]</td></tr><tr><td align="left">KNN</td><td align="left">Number of neighbours</td><td align="left">Default</td></tr><tr><td align="left">LR</td><td align="left">C</td><td align="left">[0.001, 0.01, 0.1, 1, 10, 100]</td></tr><tr><td align="left">PLS</td><td align="left">#Components</td><td align="left">Default</td></tr><tr><td align="left">RF</td><td align="left">n_estimators</td><td align="left">[20, 50, 100, 200, 500]</td></tr><tr><td align="left">SVM</td><td align="left">C</td><td align="left">[1, 2, 4, 8, 16, 32]</td></tr></tbody></table><table-wrap-foot><p>Columns 2 and 3 represents the parameter name used in the Scikit-learn library and the range of parameter used to develop the model, respectively.</p></table-wrap-foot></table-wrap></p>
      <p id="Par12">In the second step, all the 72 baseline models were utilized for constructing a new feature vector. Each baseline model can provide the information on the predicted confidence of being PR antagonists. Herein, the predicted confidence is treated as a probabilistic feature (PF), where PF is in the range of 0–1. For a given compound <italic>C</italic>, its feature vector is created by concatenating all PFs generated by all the 72 baseline models, which can be defined by:<disp-formula id="Equ1"><label>1</label><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\mathrm{nFeat}(C)=\{{PF}_{BM\left(1\right)},{PF}_{BM\left(2\right)},{PF}_{BM\left(3\right)},\dots ,{PF}_{BM\left(72\right)}\}$$\end{document}</tex-math><mml:math id="M2" display="block"><mml:mrow><mml:mi mathvariant="normal">nFeat</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>C</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mo stretchy="false">{</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="italic">PF</mml:mi></mml:mrow><mml:mrow><mml:mi>B</mml:mi><mml:mi>M</mml:mi><mml:mfenced close=")" open="("><mml:mn>1</mml:mn></mml:mfenced></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="italic">PF</mml:mi></mml:mrow><mml:mrow><mml:mi>B</mml:mi><mml:mi>M</mml:mi><mml:mfenced close=")" open="("><mml:mn>2</mml:mn></mml:mfenced></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="italic">PF</mml:mi></mml:mrow><mml:mrow><mml:mi>B</mml:mi><mml:mi>M</mml:mi><mml:mfenced close=")" open="("><mml:mn>3</mml:mn></mml:mfenced></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mo>⋯</mml:mo><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="italic">PF</mml:mi></mml:mrow><mml:mrow><mml:mi>B</mml:mi><mml:mi>M</mml:mi><mml:mfenced close=")" open="("><mml:mn>72</mml:mn></mml:mfenced></mml:mrow></mml:msub><mml:mo stretchy="false">}</mml:mo></mml:mrow></mml:mrow></mml:math><graphic xlink:href="41598_2022_20143_Article_Equ1.gif" position="anchor"/></alternatives></disp-formula>where <inline-formula id="IEq1"><alternatives><tex-math id="M3">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${PF}_{BM\left(i\right)}$$\end{document}</tex-math><mml:math id="M4"><mml:msub><mml:mrow><mml:mi mathvariant="italic">PF</mml:mi></mml:mrow><mml:mrow><mml:mi>B</mml:mi><mml:mi>M</mml:mi><mml:mfenced close=")" open="("><mml:mi>i</mml:mi></mml:mfenced></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41598_2022_20143_Article_IEq1.gif"/></alternatives></inline-formula> is the <italic>i</italic>th PF derived from the <italic>i</italic>th baseline model (<inline-formula id="IEq2"><alternatives><tex-math id="M5">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$BM(i)$$\end{document}</tex-math><mml:math id="M6"><mml:mrow><mml:mi>B</mml:mi><mml:mi>M</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>i</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math><inline-graphic xlink:href="41598_2022_20143_Article_IEq2.gif"/></alternatives></inline-formula>) of compound <italic>C.</italic> Thus, <inline-formula id="IEq3"><alternatives><tex-math id="M7">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\mathrm{nFeat}(C)$$\end{document}</tex-math><mml:math id="M8"><mml:mrow><mml:mi mathvariant="normal">nFeat</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>C</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math><inline-graphic xlink:href="41598_2022_20143_Article_IEq3.gif"/></alternatives></inline-formula> is the 72-D feature vector and considered as a new feature vector.</p>
      <p id="Par13">In the last step, a meta-predictor was built by using the 72-D feature vector coupled with the RF algorithm (called mRF model). To improve the discriminative ability of the new feature vector, in this study, we also utilized the GA-SAR algorithm<sup><xref ref-type="bibr" rid="CR52">52</xref></sup> to determine <italic>m</italic> out of the 72 PFs, where the number of <italic>m</italic> was set within the range of 5–20 with an interval of 1. Specifically, the chromosome of the GA-SAR algorithm contains two main genes, binary (GA-gene) and parametric (GA-chrom). The binary (GA-gene) and parametric (GA-chrom) are the dominant genes of the chromosome of the GA-SAR algorithm, which are used for feature and parameter optimizations, respectively. For the mRF model, the chromosome consists of <italic>n</italic> = 72 binary genes (<italic>bg</italic><sub>i</sub>) for selecting <italic>m</italic> important PFs and 3-bit genes for optimizing the parameters of mRF (n_estimators <inline-formula id="IEq4"><alternatives><tex-math id="M9">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\in$$\end{document}</tex-math><mml:math id="M10"><mml:mo>∈</mml:mo></mml:math><inline-graphic xlink:href="41598_2022_20143_Article_IEq4.gif"/></alternatives></inline-formula> {20, 50, 100, 200, 500}). If <italic>bg</italic><sub><italic>i</italic></sub> = 1, the <italic>i</italic>th feature is selected to construct the mRF model; otherwise, the <italic>i</italic><sup><italic>th</italic></sup> feature is excluded from the optimal feature set.</p>
    </sec>
    <sec id="Sec6">
      <title>Performance evaluation</title>
      <p id="Par14">The performance evaluation results of StackPR and its baseline models were examined in terms of five well-known performance metrics, including MCC, <italic>F</italic>-value, sensitivity (Sn) and specificity (Sp), and accuracy (ACC)<sup><xref ref-type="bibr" rid="CR53">53</xref>–<xref ref-type="bibr" rid="CR55">55</xref></sup> as described follows:<disp-formula id="Equ2"><label>2</label><alternatives><tex-math id="M11">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\mathrm{MCC}=\frac{\mathrm{TP}\times \mathrm{TN}-\mathrm{FP}\times \mathrm{FN}}{\sqrt[]{(\mathrm{TP}+\mathrm{FP})(\mathrm{TP}+\mathrm{FN})(\mathrm{TN}+\mathrm{FP})(\mathrm{TN}+\mathrm{FN})}}$$\end{document}</tex-math><mml:math id="M12" display="block"><mml:mrow><mml:mi mathvariant="normal">MCC</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">TP</mml:mi><mml:mo>×</mml:mo><mml:mi mathvariant="normal">TN</mml:mi><mml:mo>-</mml:mo><mml:mi mathvariant="normal">FP</mml:mi><mml:mo>×</mml:mo><mml:mi mathvariant="normal">FN</mml:mi></mml:mrow><mml:mroot><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="normal">TP</mml:mi><mml:mo>+</mml:mo><mml:mi mathvariant="normal">FP</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="normal">TP</mml:mi><mml:mo>+</mml:mo><mml:mi mathvariant="normal">FN</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="normal">TN</mml:mi><mml:mo>+</mml:mo><mml:mi mathvariant="normal">FP</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="normal">TN</mml:mi><mml:mo>+</mml:mo><mml:mi mathvariant="normal">FN</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow/></mml:mroot></mml:mfrac></mml:mrow></mml:math><graphic xlink:href="41598_2022_20143_Article_Equ2.gif" position="anchor"/></alternatives></disp-formula><disp-formula id="Equ3"><label>3</label><alternatives><tex-math id="M13">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\mathrm{F}-\mathrm{value}=2\times \frac{\mathrm{TP}}{2\mathrm{TP}+\mathrm{FP}+\mathrm{FN}}$$\end{document}</tex-math><mml:math id="M14" display="block"><mml:mrow><mml:mi mathvariant="normal">F</mml:mi><mml:mo>-</mml:mo><mml:mi mathvariant="normal">value</mml:mi><mml:mo>=</mml:mo><mml:mn>2</mml:mn><mml:mo>×</mml:mo><mml:mfrac><mml:mi mathvariant="normal">TP</mml:mi><mml:mrow><mml:mn>2</mml:mn><mml:mi mathvariant="normal">TP</mml:mi><mml:mo>+</mml:mo><mml:mi mathvariant="normal">FP</mml:mi><mml:mo>+</mml:mo><mml:mi mathvariant="normal">FN</mml:mi></mml:mrow></mml:mfrac></mml:mrow></mml:math><graphic xlink:href="41598_2022_20143_Article_Equ3.gif" position="anchor"/></alternatives></disp-formula><disp-formula id="Equ4"><label>4</label><alternatives><tex-math id="M15">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\mathrm{Sn}=\frac{\mathrm{TP}}{\left(\mathrm{TP}+\mathrm{FN}\right)}$$\end{document}</tex-math><mml:math id="M16" display="block"><mml:mrow><mml:mi mathvariant="normal">Sn</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mi mathvariant="normal">TP</mml:mi><mml:mfenced close=")" open="("><mml:mi mathvariant="normal">TP</mml:mi><mml:mo>+</mml:mo><mml:mi mathvariant="normal">FN</mml:mi></mml:mfenced></mml:mfrac></mml:mrow></mml:math><graphic xlink:href="41598_2022_20143_Article_Equ4.gif" position="anchor"/></alternatives></disp-formula><disp-formula id="Equ5"><label>5</label><alternatives><tex-math id="M17">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\mathrm{Sp}=\frac{\mathrm{ TN}}{\left(\mathrm{TN}+\mathrm{FP}\right)}$$\end{document}</tex-math><mml:math id="M18" display="block"><mml:mrow><mml:mi mathvariant="normal">Sp</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mi mathvariant="normal">TN</mml:mi><mml:mfenced close=")" open="("><mml:mi mathvariant="normal">TN</mml:mi><mml:mo>+</mml:mo><mml:mi mathvariant="normal">FP</mml:mi></mml:mfenced></mml:mfrac></mml:mrow></mml:math><graphic xlink:href="41598_2022_20143_Article_Equ5.gif" position="anchor"/></alternatives></disp-formula><disp-formula id="Equ6"><label>6</label><alternatives><tex-math id="M19">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\mathrm{ACC}=\frac{\mathrm{TP}+\mathrm{TN}}{\left(\mathrm{TP}+\mathrm{TN}+\mathrm{FP}+\mathrm{FN}\right)}$$\end{document}</tex-math><mml:math id="M20" display="block"><mml:mrow><mml:mi mathvariant="normal">ACC</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">TP</mml:mi><mml:mo>+</mml:mo><mml:mi mathvariant="normal">TN</mml:mi></mml:mrow><mml:mfenced close=")" open="("><mml:mi mathvariant="normal">TP</mml:mi><mml:mo>+</mml:mo><mml:mi mathvariant="normal">TN</mml:mi><mml:mo>+</mml:mo><mml:mi mathvariant="normal">FP</mml:mi><mml:mo>+</mml:mo><mml:mi mathvariant="normal">FN</mml:mi></mml:mfenced></mml:mfrac></mml:mrow></mml:math><graphic xlink:href="41598_2022_20143_Article_Equ6.gif" position="anchor"/></alternatives></disp-formula>where TP and TN indicate the number of true positives and true negatives, respectively. Moreover, FP and FN represent the number of false positives and false negatives, respectively<sup><xref ref-type="bibr" rid="CR56">56</xref>–<xref ref-type="bibr" rid="CR61">61</xref></sup>.</p>
    </sec>
    <sec id="Sec7">
      <title>Molecular docking</title>
      <p id="Par15">Molecular docking was performed as a virtual screening to identify potential inhibitors for human progesterone receptors. In this study, 1168 bioactive compounds with known bioactivity described using IC<sub>50</sub>, were collected from the ChEMBL database<sup><xref ref-type="bibr" rid="CR39">39</xref></sup> and preprocessed as input ligands for investigation. The molecular structure of the ligands was generated and optimized to achieve low-energy conformers using the OpenBabel software<sup><xref ref-type="bibr" rid="CR62">62</xref></sup>. The co-crystal structure of the human progesterone receptor in complex with asoprisnil (PDB ID: 2OVH) was retrieved from the Protein Data Bank<sup><xref ref-type="bibr" rid="CR63">63</xref></sup> to be used as a receptor molecule for virtual screening. The protein structure was preprocessed by removing water molecules and adding Gasteiger charges and missing hydrogen atoms. The protein structure was additionally cleaned up by repairing bonds and removing non-polar hydrogens and lone pair atoms using MGLTools<sup><xref ref-type="bibr" rid="CR64">64</xref></sup>. Consequently, grid boxes with the dimensions of 40 × 40 × 60 Angstrom were applied to the center of ligands inside the binding cavity of the protein receptor. Parameters for molecular docking were defined by default with a seed number of 1000 using Autodock Vina<sup><xref ref-type="bibr" rid="CR65">65</xref>,<xref ref-type="bibr" rid="CR66">66</xref></sup>. The method was validated using ligand re-binding approaches and the calculated RMSD of the atomic position between co-crystallized ligand and re-binding ligand was observed to be 0.322 Angstroms which is acceptable for further investigations. The binding energy (Kcal/mol) was calculated during virtual screening using the built-in scoring function of Autodock Vina and the compounds exhibiting the lowest binding energy were chosen for further investigation. The docked poses and binding interactions were visualized using the PyMOL Molecular Graphics System, version 2.2.3 (Schrödinger LLC, 2010).</p>
    </sec>
  </sec>
  <sec id="Sec8">
    <title>Results and discussion</title>
    <sec id="Sec9">
      <title>Analysis of applicability domain</title>
      <p id="Par16">Applicability domain (AD) analysis is key for reliable model predictions which can be utilized for all models<sup><xref ref-type="bibr" rid="CR45">45</xref>,<xref ref-type="bibr" rid="CR64">64</xref>,<xref ref-type="bibr" rid="CR65">65</xref></sup>. Several approaches for AD analysis have been proposed however, herein the t-distributed stochastic neighbor embedding (t-SNE)<sup><xref ref-type="bibr" rid="CR66">66</xref>,<xref ref-type="bibr" rid="CR67">67</xref></sup> was used for visual investigation of the feature distribution pertaining to the twelve molecular fingerprints. Supplementary Fig. <xref rid="MOESM1" ref-type="media">S1</xref>A–L elucidates the 2D feature distribution space where the TRN515 and IND145 datasets are represented by red and green dots, respectively. In order for the compounds to fall within the AD of the model, compounds from the IND145 dataset must be present in the defined boundary of the TRN515 dataset. Conversely, compounds are considered outside the AD of the model if they fall beyond the established boundary stated above. From Supplementary Fig. <xref rid="MOESM1" ref-type="media">S1</xref>, the chemical spaces for all twelve molecular fingerprints were observed to be overlapping for both the TRN515 and IND145 datasets. Thus, it can be inferred that the AD is well defined for these twelve molecular fingerprint-based models developed herein.</p>
    </sec>
    <sec id="Sec10">
      <title>Performance evaluation of different molecular descriptors and ML algorithms</title>
      <p id="Par17">Here, we assessed the performance of several ML classifiers trained using utilizing twelve molecular descriptors and six ML algorithms. All the 72 classifiers (6 MLs × 12 descriptors) were assessed by using tenfold cross-validation and independent tests. The performance evaluation results of the 72 classifiers are provided in Fig. <xref rid="Fig2" ref-type="fig">2</xref> and Supplementary Tables <xref rid="MOESM1" ref-type="media">S1</xref>–<xref rid="MOESM1" ref-type="media">S4</xref>. Note that the classifier with the highest MCC was deemed to be the best-performing classifier in this study. Supplementary Table <xref rid="MOESM1" ref-type="media">S3</xref> shows that the top-five molecular descriptors having the highest cross-validation performance were Circle, KR, CKD, CKDExt, and Hybrid with corresponding average ± standard deviation and MCC of 0.834 ± 0.018, 0.802 ± 0.023, 0.797 ± 0.024, 0.796 ± 0.014, and 0.784 ± 0.013, respectively. In the case of performance results of the six ML methods, Supplementary Table <xref rid="MOESM1" ref-type="media">S4</xref> shows that ET and RF achieve superior performance in terms of MCC with a range of 0.768–0.770. It could be noticed that the top-five classifiers having the highest cross-validation performance consisted of ET-Circle, RF-Circle, SVM-Circle, LR-Circle, and LR-CKD with corresponding MCC of 0.850, 0.846, 0.843, 0.842 and 0.841, respectively (Fig. <xref rid="Fig2" ref-type="fig">2</xref> and Supplementary Table <xref rid="MOESM1" ref-type="media">S1</xref>). Interestingly, four out of the top-five classifiers were developed using the Circle descriptor. This indicates that the Circle descriptor was beneficial for the identification of PR antagonists. For the performance on the IND145 dataset, the top-five classifiers yielded MCC with a range of 0.849–0.881. Although the best-performing classifier (ET-Circle) could perform well in the identification of PR antagonists, ensemble models that can automatically integrate the individual strengths of the above-mentioned classifiers are admissible<sup><xref ref-type="bibr" rid="CR45">45</xref>,<xref ref-type="bibr" rid="CR49">49</xref>,<xref ref-type="bibr" rid="CR50">50</xref>,<xref ref-type="bibr" rid="CR67">67</xref></sup>.<fig id="Fig2"><label>Figure 2</label><caption><p>Performance evaluations of top 30 baseline models. (<bold>A</bold>, <bold>B</bold>) Cross-validation ACC and MCC of top 30 baseline models. (<bold>C</bold>, <bold>D</bold>) Independent test ACC and MCC of top 30 baseline models.</p></caption><graphic xlink:href="41598_2022_20143_Fig2_HTML" id="MO2"/></fig></p>
    </sec>
    <sec id="Sec11">
      <title>Construction of StackPR</title>
      <p id="Par18">Although the ET-Circle model has yielded good performances, its overall prediction performance is still unsatisfactory for real therapeutic applications. Thus, we herein employed an ensemble approach that could take advantage of several ML-based classifiers to construct a stable stacked model. Specifically, we built two mRF models coupled with two types of new feature vectors, including the 72-D and m-D feature vectors (referred herein as the optimal model and control, respectively). The 72-D feature vector was obtained by all the 72 PFs, while the m-D feature vector was obtained from the GA-SAR algorithm. Table <xref rid="Tab3" ref-type="table">3</xref> provides the overall performance of the 72-D and m-D feature vectors. After performing the GA-SAR algorithm, we obtained the optimal feature set having m = 10 selected PFs derived from ten baseline models of KNN-AP2D, LR-CKDExt, SVM-CKDExt, ET-CKDExt, KNN-MACCS, RF-PubChem, SVM-KR, LR-FP4, RF-Circle, and PLS-Hybrid. As shown in Table <xref rid="Tab3" ref-type="table">3</xref>, the 10-D feature vector achieves the overall best performance compared with the 72-D feature vector on both the TRN515 and IND145 datasets in approximately all performance metrics, except for AUC. Remarkably, ACC, Sn, and MCC of the 10-D feature vector were 3.45, 4.30, and 7.31% higher than the 72-D feature vector on the independent test dataset. Altogether, the mRF model in conjunction with the 10-D feature vector (called the optimal feature vector) is deemed to be the final model herein and referred to as StackPR for the convenience of discussion.<table-wrap id="Tab3"><label>Table 3</label><caption><p>Performance comparison of the optimal model and control on the training and independent test datasets.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Evaluation strategy</th><th align="left">Method<sup>a</sup></th><th align="left">Dimension</th><th align="left">ACC</th><th align="left">Sn</th><th align="left">Sp</th><th align="left">MCC</th><th align="left">AUC</th></tr></thead><tbody><tr><td align="left" rowspan="2">Cross-validation</td><td align="left">Control</td><td align="left">72</td><td char="." align="char">0.927</td><td char="." align="char">0.946</td><td char="." align="char">0.894</td><td char="." align="char">0.843</td><td char="." align="char">0.972</td></tr><tr><td align="left">Optimal</td><td align="left">10</td><td char="." align="char">0.950</td><td char="." align="char">0.970</td><td char="." align="char">0.913</td><td char="." align="char">0.893</td><td char="." align="char">0.976</td></tr><tr><td align="left" rowspan="2">Independent test</td><td align="left">Control</td><td align="left">72</td><td char="." align="char">0.931</td><td char="." align="char">0.935</td><td char="." align="char">0.923</td><td char="." align="char">0.852</td><td char="." align="char">0.984</td></tr><tr><td align="left">Optimal</td><td align="left">10</td><td char="." align="char">0.966</td><td char="." align="char">0.978</td><td char="." align="char">0.942</td><td char="." align="char">0.925</td><td char="." align="char">0.978</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>The optimal model and control are developed by using mRF models coupled with the 72-D and 10-D feature vectors, respectively.</p></table-wrap-foot></table-wrap></p>
    </sec>
    <sec id="Sec12">
      <title>Stacking improves the prediction performance</title>
      <p id="Par19">In this section, we aim to reveal the effectiveness of the stacking strategy by comparing the performance of StackPR with the top five baseline models as judged by the cross-validation MCC. These baseline models included ET-Circle, RF-Circle, SVM-Circle, LR-Circle, and LR-CKD. The detailed results of their performance evaluations are provided in Fig. <xref rid="Fig3" ref-type="fig">3</xref>, Table <xref rid="Tab4" ref-type="table">4</xref>, and Supplementary Table <xref rid="MOESM1" ref-type="media">S5</xref>. Table <xref rid="Tab4" ref-type="table">4</xref> shows that StackPR’s ACC, Sn, MCC, and <italic>F</italic>-value were better than the top five baseline models on both the TRN515 and IND145 datasets. Interestingly, ACC, Sn, and MCC of StackPR were 0.950, 0.970, 0.893, and 0.958, which were 1.90, 2.70, 4.31, and 1.52%, respectively, higher than the best-performing baseline model ET-Circle in the TRN515 dataset. StackPR also attained a better performance as compared with ET-Circle on the IND145 dataset. For the performance on the independent test dataset, StackPR’s ACC, Sn, and MCC were 0.966, 0.978, 0.925, and 0.973, respectively. To be specific, these three-performance metrics were higher than that of the ET-Circle model by 2.07, 3.23, 4.34, and 1.67%, respectively. However, StackPR provided a slightly lower AUC as compared to the ET-Circle model (0.978 versus 0.983), StackPR could identify more true compounds against PR (TP) in terms of both the TRN515 (299 versus 290) and IND145 (91 versus 88) datasets (Table <xref rid="Tab4" ref-type="table">4</xref> and Supplementary Table <xref rid="MOESM1" ref-type="media">S5</xref>). These results indicated that the stacking approach used in StackPR effectively integrated the advantages of the baseline models, contributing to the improvement in performance.<fig id="Fig3"><label>Figure 3</label><caption><p>Performance comparison of StackPR with the top five baseline models on the Main-TRN (<bold>A</bold>, <bold>B</bold>) and Main-IND (<bold>C</bold>, <bold>D</bold>) datasets. Prediction results of StackPR with the top five baseline models in terms of MCC, Sn, Sp and MCC (<bold>A</bold>, <bold>C</bold>). ROC curves and AUC values of StackPR with the top five baseline models (<bold>B</bold>, <bold>D</bold>).</p></caption><graphic xlink:href="41598_2022_20143_Fig3_HTML" id="MO3"/></fig><table-wrap id="Tab4"><label>Table 4</label><caption><p>Performance comparison of StackPR and top five baseline models on the training and independent test datasets.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Evaluation strategy</th><th align="left">Method</th><th align="left">ACC</th><th align="left">Sn</th><th align="left">Sp</th><th align="left">MCC</th><th align="left">AUC</th><th align="left"><italic>F</italic>-value</th></tr></thead><tbody><tr><td align="left" rowspan="6">Cross-validation</td><td align="left">ET-circle</td><td char="." align="char">0.931</td><td char="." align="char">0.943</td><td char="." align="char">0.909</td><td char="." align="char">0.850</td><td char="." align="char">0.976</td><td char="." align="char">0.943</td></tr><tr><td align="left">RF-circle</td><td char="." align="char">0.929</td><td char="." align="char">0.943</td><td char="." align="char">0.904</td><td char="." align="char">0.846</td><td char="." align="char">0.983</td><td char="." align="char">0.942</td></tr><tr><td align="left">SVM-circle</td><td char="." align="char">0.927</td><td char="." align="char">0.935</td><td char="." align="char">0.913</td><td char="." align="char">0.843</td><td char="." align="char">0.983</td><td char="." align="char">0.940</td></tr><tr><td align="left">LR-circle</td><td char="." align="char">0.927</td><td char="." align="char">0.946</td><td char="." align="char">0.894</td><td char="." align="char">0.842</td><td char="." align="char">0.983</td><td char="." align="char">0.939</td></tr><tr><td align="left">LR-CKD</td><td char="." align="char">0.927</td><td char="." align="char">0.957</td><td char="." align="char">0.875</td><td char="." align="char">0.841</td><td char="." align="char">0.981</td><td char="." align="char">0.939</td></tr><tr><td align="left">StackPR</td><td char="." align="char">0.950</td><td char="." align="char">0.970</td><td char="." align="char">0.913</td><td char="." align="char">0.893</td><td char="." align="char">0.976</td><td char="." align="char">0.958</td></tr><tr><td align="left" rowspan="6">Independent test</td><td align="left">ET-circle</td><td char="." align="char">0.945</td><td char="." align="char">0.946</td><td char="." align="char">0.942</td><td char="." align="char">0.881</td><td char="." align="char">0.983</td><td char="." align="char">0.957</td></tr><tr><td align="left">RF-circle</td><td char="." align="char">0.945</td><td char="." align="char">0.946</td><td char="." align="char">0.942</td><td char="." align="char">0.881</td><td char="." align="char">0.983</td><td char="." align="char">0.957</td></tr><tr><td align="left">SVM-circle</td><td char="." align="char">0.938</td><td char="." align="char">0.946</td><td char="." align="char">0.923</td><td char="." align="char">0.866</td><td char="." align="char">0.983</td><td char="." align="char">0.951</td></tr><tr><td align="left">LR-circle</td><td char="." align="char">0.931</td><td char="." align="char">0.957</td><td char="." align="char">0.885</td><td char="." align="char">0.849</td><td char="." align="char">0.981</td><td char="." align="char">0.947</td></tr><tr><td align="left">LR-CKD</td><td char="." align="char">0.931</td><td char="." align="char">0.946</td><td char="." align="char">0.904</td><td char="." align="char">0.850</td><td char="." align="char">0.978</td><td char="." align="char">0.946</td></tr><tr><td align="left">StackPR</td><td char="." align="char">0.966</td><td char="." align="char">0.978</td><td char="." align="char">0.942</td><td char="." align="char">0.925</td><td char="." align="char">0.978</td><td char="." align="char">0.973</td></tr></tbody></table></table-wrap></p>
    </sec>
    <sec id="Sec13">
      <title>Analysis of new feature vector</title>
      <p id="Par20">In this section, we investigated the performance of the optimal feature vector by testing and comparing its performance with the twelve conventional molecular descriptors. Supplementary Tables <xref rid="MOESM1" ref-type="media">S6</xref>–<xref rid="MOESM1" ref-type="media">S7</xref> provide the predictive performance of the optimal feature vector against the twelve conventional molecular descriptors. For the sake of fairness, the RF classifier was employed to train different models coupled with the twelve molecular descriptors and build respective prediction models. For the convenience of the comparison purpose, we conducted the performance comparison of the optimal feature vector with only the top five molecular descriptors having the highest cross-validation MCC, including Circle, KR, MACCS, FP4, and CKDExt. We noticed that the top five beneficial molecular descriptors achieved the overall best performance as compared with the top five beneficial molecular descriptors on both the TRN515 and IND145 datasets as judged by ACC, Sn, and Sp (Supplementary Tables <xref rid="MOESM1" ref-type="media">S6</xref>–<xref rid="MOESM1" ref-type="media">S7</xref>). Remarkably, for the performance on the IND145 dataset, the optimal feature vector’s ACC, Sn, and MCC were 2.07–6.90, 2.15–4.3,0, and 4.34–15.18%, respectively, higher than that of the top five molecular descriptors. In addition, the 2D feature space of the optimal feature vector and the top five molecular descriptors were depicted by using the t-distributed stochastic neighbor embedding (t-SNE)<sup><xref ref-type="bibr" rid="CR68">68</xref>,<xref ref-type="bibr" rid="CR69">69</xref></sup>, where the red and green dots represent positive (active compounds) and negative (inactive compounds) samples, respectively (Fig. <xref rid="Fig4" ref-type="fig">4</xref>). Overall, we observe that the distributions of the five top-five beneficial molecular descriptors did not show a clear separation between the two classes (Fig. <xref rid="Fig4" ref-type="fig">4</xref>A–E). On the other hand, the optimal feature vector was able to provide a clear separation between the two classes (Fig. <xref rid="Fig4" ref-type="fig">4</xref>F). Altogether, these results indicate that our proposed 10-D feature vector derived from the combination of several molecular descriptors and ML algorithms had a more discriminative ability to capture the key information of active and inactive compounds against PR, contributing to the performance improvement.<fig id="Fig4"><label>Figure 4</label><caption><p>t-distributed stochastic neighbor embedding (t-SNE) distribution of positive and negative samples on the training dataset.</p></caption><graphic xlink:href="41598_2022_20143_Fig4_HTML" id="MO4"/></fig></p>
    </sec>
    <sec id="Sec14">
      <title>Mechanistic interpretation of StackPR</title>
      <p id="Par21">To better understand the impact governing each feature of the StackPR model, an analysis of the feature importance was conducted. Herein, we utilized the SHAP framework<sup><xref ref-type="bibr" rid="CR70">70</xref></sup> to calculate the value of each feature while also shedding light on the output of the model. SHAP is a game-theoretic approach used to explain the output of any ML classifier and represents a crucial role in many bioinformatics applications. The positive and negative SHAP values indicate that the prediction model better favors active or inactive compounds, respectively. Figure <xref rid="Fig5" ref-type="fig">5</xref> shows that the top five informative PFs based on SHAP values were derived from RF-Circle, SVM-KR, LR-CKDExt, ET-CKDExt, and SVM-CKDExt. Interesting, RF-Circle is found in both the top-performing classifier and the top-ranked informative PFs based on SHAP values. As can be seen in Fig. <xref rid="Fig6" ref-type="fig">6</xref>, the top-twenty most important informative features as deduced by SHAP values were PubChemFP499, PubChemFP335, PubChemF383, PubChemFP542 PubChemFP566, PubChemFP652, PubChemFP382, PubChemFP338, PubChemFP260, PubChemFP569, PubChemFP392, PubChemFP712, PubChemFP420, PubChemFP717, PubChemFP780, PubChemFP840, PubChemFP590, PubChemFP145, PubChemFP430, and PubChemFP467. In addition, as stated above, high SHAP value (positive scale) with high feature value (represented by red) which are most likely to have an impact on the substructure of the compounds were seen in twelve out of top-twenty informative features (Fig. <xref rid="Fig6" ref-type="fig">6</xref> and Table <xref rid="Tab5" ref-type="table">5</xref>) representing, five aliphatic hydrocarbons (i.e., PubChemFP335, PubChemFP712, PubChemFP717, PubChemFP780, PubChemFP430), five nitrogen-containing (i.e., PubChemFP338, PubChemFP569, PubChemFP392, PubChemFP145, PubChemFP467), one alcohol (i.e., PubChemFP840) and one carbonyl group (i.e., PubChemFP420; which is common to several classes of organic compounds such as aldehyde and ketone). Therefore, it can be inferred that aliphatic hydrocarbons and nitrogen-containing compounds represent substructures that have a high impact on PR antagonism. Further exploration into the PubChem substructure descriptions (Table <xref rid="Tab5" ref-type="table">5</xref>), offers observations that bioisoteric transformations occur when the CH group of compounds containing heteroaromatic rings are substituted with a N atom (i.e., PubChemFP145). This substation exerts antagonistic effects by mirroring the binding of natural ligands<sup><xref ref-type="bibr" rid="CR71">71</xref></sup>. Furthermore, the above-mentioned features belong mainly to N-methylmethanamine, ethylenediamine, isopropylamine etc. which are all precursors of many significant PR antagonists such as mifepristone, lonaprisan and vilaprisan. However, several steroidal SPRMs with a dimethylamino substituent have shown an increase in liver enzyme upon continued use<sup><xref ref-type="bibr" rid="CR72">72</xref></sup>. Nevertheless, novel analogues of mifepristone with increased PR selectivity over GR has been identified<sup><xref ref-type="bibr" rid="CR73">73</xref></sup>. As for the aliphatic substructures observed in Table <xref rid="Tab5" ref-type="table">5</xref>, Nishiyama et al.<sup><xref ref-type="bibr" rid="CR74">74</xref></sup>, identified that alkyl substitutions at 4-Alkyl analogs of phenanthridin-6(5H)-one skeleton show potent PR antagonistic activity. Additionally, the 1-propynyl substituent at the C-17 position of mifepristone accounts for its high PR binding affinity<sup><xref ref-type="bibr" rid="CR75">75</xref></sup>. Similarly, Richardson et al.<sup><xref ref-type="bibr" rid="CR76">76</xref></sup>, discovered that alkyl substituents on the N1 of the indole skeleton played an important role in the binding affinity of compounds to PR whereby changing the substituent from methyl to ethyl and then from ethyl to isopropyl afforded 7- and fivefold improvements in potency, respectively. Moreover, the indole with the isopropyl substituent showed higher PR selectivity over GR and AR in both functional and binding assays<sup><xref ref-type="bibr" rid="CR76">76</xref></sup>. Taken together, the important PubChem features as determined by SHAP are effective as potential PR antagonist substructures.<fig id="Fig5"><label>Figure 5</label><caption><p>Feature importance from StackPR as ranked by SHAP values based on the training datasets. Such SHAP values represent the directionality of features where positive and negatives SHAP values influences the predictions toward positive and negative samples, respectively.</p></caption><graphic xlink:href="41598_2022_20143_Fig5_HTML" id="MO5"/></fig><fig id="Fig6"><label>Figure 6</label><caption><p>Feature importance from the RF-PubChem model as ranked by SHAP values based on the training datasets. Such SHAP values represent the directionality of features where positive and negatives SHAP values influences the predictions toward positive and negative samples, respectively.</p></caption><graphic xlink:href="41598_2022_20143_Fig6_HTML" id="MO6"/></fig><table-wrap id="Tab5"><label>Table 5</label><caption><p>Summary of top-twenty important features ranked by SHAP values along with their corresponding SMARTS patterns, chemical structure and substructure description.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Feature</th><th align="left">SMARTS pattern</th><th align="left">Substructure description</th></tr></thead><tbody><tr><td align="left">PubChemFP499</td><td align="left">N–C:C:N</td><td align="left">Ethylenediamine</td></tr><tr><td align="left">PubChemFP335</td><td align="left">C(~ C)(~ C)(~ C)(~ H)</td><td align="left">2-Methylpropane</td></tr><tr><td align="left">PubChemF383</td><td align="left">C(~ S)(:C)</td><td align="left">Ethanethiol</td></tr><tr><td align="left">PubChemFP542</td><td align="left">O–C:C–[#1]</td><td align="left">Ethanol</td></tr><tr><td align="left">PubChemFP566</td><td align="left">O–C–C–N</td><td align="left">2-Aminoethanol</td></tr><tr><td align="left">PubChemFP652</td><td align="left">O–C:C:C–N</td><td align="left">3-Aminopropan-1-ol</td></tr><tr><td align="left">PubChemFP382</td><td align="left">C(~ O)(:C)(:C)</td><td align="left">Propan-2-ol</td></tr><tr><td align="left">PubChemFP338</td><td align="left">C(~ C)(~ C)(~ H)(~ N)</td><td align="left">Propan-2-amine</td></tr><tr><td align="left">PubChemFP260</td><td align="left">≥ 3 hetero-aromatic rings</td><td align="left">Greater than or equal to 3 heterocyclic aromatic rings</td></tr><tr><td align="left">PubChemFP569</td><td align="left">N–C–C–N</td><td align="left">Ethylenediamine</td></tr><tr><td align="left">PubChemFP392</td><td align="left">N(~ C)(~ C)(~ H)</td><td align="left">N-Methylmethanamine</td></tr><tr><td align="left">PubChemFP712</td><td align="left">C–C(C)–C(C)–C</td><td align="left">2,3-Dimethylbutane</td></tr><tr><td align="left">PubChemFP420</td><td align="left">C=O</td><td align="left">Carbonyl group</td></tr><tr><td align="left">PubChemFP717</td><td align="left">Cc1ccc(C1)cc1</td><td align="left">Aromatic and aliphatic carbons—(1-Ethyl-3-methylcyclopentane)</td></tr><tr><td align="left">PubChemFP780</td><td align="left">CC1CCC(C1)CC1</td><td align="left">Aliphatic carbons (1-Ethyl-3-methylcyclopentane)</td></tr><tr><td align="left">PubChemFP840</td><td align="left">CC1CC(O)CC1</td><td align="left">3-Methylcyclopentan-1-ol</td></tr><tr><td align="left">PubChemFP590</td><td align="left">C–C:C–O–[#1]</td><td align="left">Propan-1-ol</td></tr><tr><td align="left">PubChemFP145</td><td align="left">≥ 1 saturated or aromatic nitrogen- containing ring size 5</td><td align="left">Greater than or equal to 1 saturated or aromatic nitrogen-containing ring of size 5</td></tr><tr><td align="left">PubChemFP430</td><td align="left">C(–C)(–C)(=C)</td><td align="left">2-Methylprop-1-ene</td></tr><tr><td align="left">PubChemFP467</td><td align="left">C=N–N–C</td><td align="left">N-(Methylideneamino)methanamine</td></tr></tbody></table></table-wrap></p>
    </sec>
    <sec id="Sec15">
      <title>Case study</title>
      <p id="Par22">In this section, we used molecular docking to visualize the binding interactions of compounds to PR in comparison to known modulators by using the AutoDock Vina software<sup><xref ref-type="bibr" rid="CR66">66</xref></sup>. Out of all the compounds, the top-ten compounds with the highest docking scores indicating the highest binding affinity were selected for evaluation. As can be seen in Supplementary Fig. <xref rid="MOESM1" ref-type="media">S2</xref>, the docking score of the top-ten compounds were − 12.67, − 12.33, − 11.82, − 11.67, − 11.48, − 11.11, − 11.10, − 11.06, − 11.03, − 11.01 kcal/mol with corresponding IC<sub>50</sub> values of 0.33, 0.2, 0.025, 3.64, 0.27, 34, 4.6, 0.63, 0.63 and 19 nM, respectively. Of note, the IC<sub>50</sub> values are all in the nM range highlighting that all the top-ten compounds showed strong binding affinity to PR as determined through in vitro experiments.</p>
      <p id="Par23">A further in-depth analysis of these top-ten compounds (Supplementary Fig. <xref rid="MOESM1" ref-type="media">S2</xref>) reveals the top scaffolds pertaining to a typical steroid skeleton consisting of fused rings with three six-member rings and one five-member ring<sup><xref ref-type="bibr" rid="CR77">77</xref></sup> (nine out of ten compounds), nitrogen-containing compounds (nine out of ten compounds), and aliphatic compounds (all ten compounds). The compounds with the aliphatic substructures have a structural similarity not only to progesterone but also to already known PR antagonists such as asoprisnil, mifepristone and onapristone<sup><xref ref-type="bibr" rid="CR78">78</xref></sup>. In addition, various derivatives of mifepristone such as aglepristone, lilopristone, onapristone, and telapristone have been synthesized and some are currently in clinical trials. Nine out of the top-ten compounds, resembles asoprisnil and mifepristone, which are well-known PR antagonists. Thus, the binding of PR to these compounds with high affinity is valid.</p>
      <p id="Par24">The docked pose of the compound with the highest docking score (i.e., CHEMBL259879; − 12.67 kcal/mol) was further investigated for its binding interactions to PR (PDB ID: 2OVH) and is portrayed in Fig. <xref rid="Fig7" ref-type="fig">7</xref>A and C. In addition, the binding interactions of PR (PDBID: 2OVH) with its co-crystallized structure, a SPRM (i.e., asoprisnil) in the docked pose were also elucidated using PyMOL (Fig. <xref rid="Fig7" ref-type="fig">7</xref>A,B). Asoprisnil exhibits antagonistic activities in endometrium, ovary, and breast tissues<sup><xref ref-type="bibr" rid="CR79">79</xref></sup>. As observed from Fig. <xref rid="Fig7" ref-type="fig">7</xref>B, the docking pose between PR and asoprisnil, reveal vital interactions in the active site that consists of hydrogen bonds with NE2 and NH2 of residues Q725 and R766 at a distance of 2.91 Å and 2.74 Å, respectively, which are depicted with the blue dash lines. Additionally, residues L721, W755 and L797, were observed to form hydrophobic interactions at distances of 3.53 Å, 3.48 Å and 3.96 Å, respectively (gray dash lines). In addition, a water bridge (light purple dash lines) was shown connecting NH1 of R766 and O14 of asoprisnil. Furthermore, a perpendicular pi-stacking (depicted as a green dash line) with the phenyl ring of residue F778 was also observed at a distance of 5.32 Å. On the other hand, the docked pose of CHEMBL259879 bound to PR (Fig. <xref rid="Fig7" ref-type="fig">7</xref>C) reveals the interacting binding pocket residues to be comprised of Q725, and R766 forming hydrogen bonds (shown as blue dash lines) at distances of 3.66 Å, and 3.11 Å, respectively. Moreover, residues L715, L718, L721, L726, L763, W755, F778, L797, and Y890 showed binding through hydrophobic interactions that are represented with gray dash lines. In addition, two pi-pi interactions were observed, one being a staggered stacking (i.e., parallel pi-stacking, shown as a light green dash line) with W755 and the other being a pi-teeing (i.e., perpendicular pi-stacking, shown as a dark green dash line) with F778 at distances of 4.10 Å and 5.12 Å, respectively. Both these types of pi-pi interactions are known to be electrostatically attractive<sup><xref ref-type="bibr" rid="CR80">80</xref></sup>. These results indicate that the top compound as revealed by molecular docking (i.e., CHEMBL259879) forms interactions in the binding pocket of PR that are comprised of more residues than asoprisnil. These outcomes are in accordance with SPRM binding analysis highlighting the relevance of hydrophobicity in the interactions of the ligand and catalytic residues, L718, and Q725<sup><xref ref-type="bibr" rid="CR35">35</xref></sup>. Therefore, these interactions could be useful in determining the top substructures needed for a high-affinity PR antagonist. Additionally, competitive binding to PR was determined from the ability of compound CHEMBL259879 to exhibit antagonistic activity in a CHO (chinese hamster ovary) cell line-based assay in PubChem’s bioassay record with an IC<sub>50</sub> of 0.33 nM<sup><xref ref-type="bibr" rid="CR81">81</xref>,<xref ref-type="bibr" rid="CR82">82</xref></sup>. Overall, these results indicate that CHEMBL259879 could be a good candidate for PR antagonism.<fig id="Fig7"><label>Figure 7</label><caption><p>Superimposed docked pose of PR with co-crystallized ligand (PDB ID: 2OVH) (i.e., asoprisnil, <bold>A</bold>) and the top scoring compound as measured by AutoDock Vina (i.e., CHEMBL259879, <bold>A</bold>). Close-up views of the binding cavity of PR-asoprisnil (<bold>B</bold>) and PR-CHEMBL259879 (<bold>C</bold>). Hydrogen bond and hydrophobic residues are shown in red and green colored text boxes, respectively.</p></caption><graphic xlink:href="41598_2022_20143_Fig7_HTML" id="MO7"/></fig></p>
      <p id="Par25">Taking it a step further, we superimposed the ligands asoprisnil and CHEMBL259879 in the PR binding pocket to elucidate their molecular similarities and differences. As can be seen in Fig. <xref rid="Fig8" ref-type="fig">8</xref>, CHEMBL259879 overlays well over asoprisnil with differing scaffold substitutions at C11 and C17. A cyclopentone at C11 and a benzene with a pyridine substitution at C17 was revealed for CHEMBL259879 while asoprisnil has a benzaldehyde oxime at C11 and a dimethoxymethyl at C17. Furthermore, a key role in the binding of ligands to PR and/or GR receptor is observed to be modifications made near the C17 propinyl group (Fig. <xref rid="Fig8" ref-type="fig">8</xref>)<sup><xref ref-type="bibr" rid="CR83">83</xref>,<xref ref-type="bibr" rid="CR84">84</xref></sup>. In addition, substitutions pertaining to ethyl and pentynyl at the hydrophobic C17 produces higher PR antagonism as compared to that of asoprisnil or mifepristone<sup><xref ref-type="bibr" rid="CR85">85</xref></sup>. Minor changes in the C17 such as a phenyl group with small, stabilizing electron-withdrawing substituents, (i.e., F, Cl, Br, and CF3), was shown to prominently increase the potency of compounds while hightening selectivity over GR<sup><xref ref-type="bibr" rid="CR86">86</xref></sup>. As can be seen in Supplementary Fig. <xref rid="MOESM1" ref-type="media">S2</xref>, two of the top-ten compounds (i.e., compounds (<bold>3</bold>) and (<bold>10</bold>)) contained those with the above-mentioned properties.<fig id="Fig8"><label>Figure 8</label><caption><p>Overlaid structures of PR-Asoprisnil and PR-CHEMBL259879 where the carbons are colored orange and yellow, respectively. The C-11 and C-17 substituents are highlighted to show their effect on antagonist activity and PR selectivity, respectively.</p></caption><graphic xlink:href="41598_2022_20143_Fig8_HTML" id="MO8"/></fig></p>
      <p id="Par26">The substitution of 4-(dimethylamino) phenyl group at the C11 position (Fig. <xref rid="Fig8" ref-type="fig">8</xref>) is known to define the degree of antagonistic activity, as per the literature<sup><xref ref-type="bibr" rid="CR83">83</xref>,<xref ref-type="bibr" rid="CR84">84</xref></sup>. In addition, small substituents such as methyl revealed powerful agonistic properties against PR in comparison to phenyl derivatives which displayed varying degrees of antagonistic activity<sup><xref ref-type="bibr" rid="CR83">83</xref>,<xref ref-type="bibr" rid="CR84">84</xref></sup>. Interestingly, we can observe that nine of the top-ten compounds (i.e., compounds (<bold>1</bold>), (<bold>2</bold>), (<bold>3</bold>), (<bold>4</bold>), (<bold>5</bold>), (<bold>7</bold>), (<bold>8</bold>), (<bold>9</bold>) and (<bold>10</bold>)) contain substitutions of either one or two phenyl derivatives at the C11 position. Furthermore, research suggests that, nitrogen heterocycle substitution at C11 (i.e., compounds (<bold>1</bold>), (<bold>4</bold>), (<bold>5</bold>), (<bold>9</bold>) and (<bold>10</bold>)) especially in compounds devoid of a center of electronegativity in this region show the highest antagonistic activity<sup><xref ref-type="bibr" rid="CR82">82</xref>,<xref ref-type="bibr" rid="CR87">87</xref></sup>. Altogether, the top-ten compounds as determined through molecular docking, have the potential to be good candidate compounds as they have been validated for binding affinity in vitro with IC<sub>50</sub> in the nM range. Furthermore, these compounds exhibit molecular substitutions which have been reported as favorable for high PR antagonism while simultaneously increasing selectivity over GR.</p>
    </sec>
    <sec id="Sec16">
      <title>StackPR web server</title>
      <p id="Par27">To guarantee that the StackPR predictor can perform the high-throughput identification of PR antagonists in a cost-effective manner, we have developed a user-friendly webserver (named StackPR) which is available at <ext-link ext-link-type="uri" xlink:href="http://pmlabstack.pythonanywhere.com/StackPR">http://pmlabstack.pythonanywhere.com/StackPR</ext-link><underline>.</underline> To obtain the prediction results, users are recommended to input the SMILES notation in the textbox. In addition, a step-by-step guideline on the usage of the StackPR webserver is provided at <ext-link ext-link-type="uri" xlink:href="http://pmlabstack.pythonanywhere.com/about_StackPR">http://pmlabstack.pythonanywhere.com/about_StackPR</ext-link>.</p>
    </sec>
  </sec>
  <sec id="Sec17">
    <title>Conclusions</title>
    <p id="Par28">Breast cancer is the most detected cancer among women while gynecological cancers such as ovarian and endometrial cancers rank sixth and eighth, respectively. PR, a steroid nuclear receptor has emerged as a potential therapeutic target owing to its implications for the prognosis and development of breast cancer. Despite extensive research and high in vitro antagonistic activity of many compounds to PR, none have passed phase III clinical trials as yet. Thus, the discovery of newer PR antagonists is greatly needed. Here, we present StackPR, a novel stacked ML-based approach for the high-throughput identification of PR antagonists. We integrated six popular ML algorithms (i.e., ET, KNN, LR, PLS, RF, and SVM) coupled with twelve conventional molecular descriptors (i.e., AP2D, Circle, CKD, CKDExt, CKDGraph, Estate, FP4, FP4C, Hybrid, KR, MACCS, and PubChem) to develop the final meta-predictor using a stacking strategy. Experimental results showed that StackPR achieved impressive predictive performance with ACC, MCC, and AUC of 0.966, 0.925and 0.978, respectively on the independent test dataset. The high MCC value indicates that the proposed StackPR can effectively complement experimental studies to reduce the number of both false-positive and false-negative cases. Furthermore, analysis results based on the SHAP algorithm and molecular docking indicate that aliphatic hydrocarbons and nitrogen-containing substructures as well as substitutions at the C-11 and C-17 carbons of the steroid skeleton were the most important features for having PR antagonist activity. Moreover, non-steroidal derivatives also offer great promise particularly if potent substituents are involved. Remarkably, the docking pose of the top-scoring compound when further analyzed for binding interactions, revealed that hydrogen bonds and hydrophobic interactions were in accordance with reported PR antagonist activities. We anticipate that StackPR will be a powerful and useful computational tool for the large-scale identification of unknown PR antagonist candidates for follow-up experimental validation.
</p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Information</title>
    <sec id="Sec18">
      <p>
        <supplementary-material content-type="local-data" id="MOESM1">
          <media xlink:href="41598_2022_20143_MOESM1_ESM.docx">
            <caption>
              <p>Supplementary Information.</p>
            </caption>
          </media>
        </supplementary-material>
      </p>
    </sec>
  </sec>
</body>
<back>
  <fn-group>
    <fn>
      <p>
        <bold>Publisher's note</bold>
      </p>
      <p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
    </fn>
  </fn-group>
  <sec>
    <title>Supplementary Information</title>
    <p>The online version contains supplementary material available at 10.1038/s41598-022-20143-5.</p>
  </sec>
  <ack>
    <title>Acknowledgements</title>
    <p>This research was supported by Mahidol University to N.S. This work is also supported by College of Arts, Media and Technology, Chiang Mai University and partially supported by Chiang Mai University and Mahidol University. For the computational resources, this work was supported by Information Technology Service Center (ITSC) of Chiang Mai University.</p>
  </ack>
  <notes notes-type="author-contribution">
    <title>Author contributions</title>
    <p>Project administration, supervision, conceptualization, analysis and investigation: W.S.; methodology, visualization, validation, software and web server development: P.C.; data collection, interpretation, and docking analysis: N.S.; writing—original draft: M.A.M., P.L., W.S., N.S. and N.A.; writing—review and editing: N.S. and W.S. All authors reviewed and approved the manuscript.</p>
  </notes>
  <notes notes-type="data-availability">
    <title>Data availability</title>
    <p>All the data used in this study are available at <ext-link ext-link-type="uri" xlink:href="http://pmlabstack.pythonanywhere.com/StackPR">http://pmlabstack.pythonanywhere.com/StackPR</ext-link>.</p>
  </notes>
  <notes id="FPar1" notes-type="COI-statement">
    <title>Competing interests</title>
    <p id="Par29">The authors declare no competing interests.</p>
  </notes>
  <ref-list id="Bib1">
    <title>References</title>
    <ref id="CR1">
      <label>1.</label>
      <mixed-citation publication-type="other">World Health Organization. <italic>Breast Cancer</italic>. <ext-link ext-link-type="uri" xlink:href="https://www.who.int/news-room/fact-sheets/detail/breast-cancer#:~:text=In%202020%2C%20there%20were%202.3,the%20world's%20most%20prevalent%20cancer">https://www.who.int/news-room/fact-sheets/detail/breast-cancer#:~:text=In%202020%2C%20there%20were%202.3,the%20world's%20most%20prevalent%20cancer</ext-link>. Accessed 9 April 2022.</mixed-citation>
    </ref>
    <ref id="CR2">
      <label>2.</label>
      <mixed-citation publication-type="other">GLOBOCAN. Estimated number of incident cases worldwide, females, all ages. <italic>International Agency for Research on Cancer 2022</italic> (2020). <ext-link ext-link-type="uri" xlink:href="https://gco.iarc.fr/today/online-analysis-multi-bars?v=2020&amp;mode=cancer&amp;mode_population=countries&amp;population=900&amp;populations=900&amp;key=total&amp;sex=2&amp;cancer=39&amp;type=0&amp;statistic=5&amp;prevalence=0&amp;population_group=0&amp;ages_group%5B%5D=0&amp;ages_group%5B%5D=17&amp;nb_items=10&amp;group_cancer=1&amp;include_nmsc=0&amp;include_nmsc_other=1&amp;type_multiple=%257B%2522inc%2522%253Atrue%252C%2522mort%2522%253Afalse%252C%2522prev%2522%253Afalse%257D&amp;orientation=horizontal&amp;type_sort=0&amp;type_nb_items=%257B%2522top%2522%253Atrue%252C%2522bottom%2522%253Afalse%257D">https://gco.iarc.fr/today/online-analysis-multi-bars?v=2020&amp;mode=cancer&amp;mode_population=countries&amp;population=900&amp;populations=900&amp;key=total&amp;sex=2&amp;cancer=39&amp;type=0&amp;statistic=5&amp;prevalence=0&amp;population_group=0&amp;ages_group%5B%5D=0&amp;ages_group%5B%5D=17&amp;nb_items=10&amp;group_cancer=1&amp;include_nmsc=0&amp;include_nmsc_other=1&amp;type_multiple=%257B%2522inc%2522%253Atrue%252C%2522mort%2522%253Afalse%252C%2522prev%2522%253Afalse%257D&amp;orientation=horizontal&amp;type_sort=0&amp;type_nb_items=%257B%2522top%2522%253Atrue%252C%2522bottom%2522%253Afalse%257D</ext-link>.</mixed-citation>
    </ref>
    <ref id="CR3">
      <label>3.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Onitilo</surname>
            <given-names>AA</given-names>
          </name>
          <name>
            <surname>Engel</surname>
            <given-names>JM</given-names>
          </name>
          <name>
            <surname>Greenlee</surname>
            <given-names>RT</given-names>
          </name>
          <name>
            <surname>Mukesh</surname>
            <given-names>BN</given-names>
          </name>
        </person-group>
        <article-title>Breast cancer subtypes based on ER/PR and Her2 expression: Comparison of clinicopathologic features and survival</article-title>
        <source>Clin. Med. Res.</source>
        <year>2009</year>
        <volume>7</volume>
        <issue>1–2</issue>
        <fpage>4</fpage>
        <lpage>13</lpage>
        <pub-id pub-id-type="doi">10.3121/cmr.2009.825</pub-id>
        <?supplied-pmid 19574486?>
        <pub-id pub-id-type="pmid">19574486</pub-id>
      </element-citation>
    </ref>
    <ref id="CR4">
      <label>4.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Li</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Wei</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Wu</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Mao</surname>
            <given-names>X</given-names>
          </name>
        </person-group>
        <article-title>The role of progesterone receptors in breast cancer</article-title>
        <source>Drug Des. Dev. Ther.</source>
        <year>2022</year>
        <volume>16</volume>
        <fpage>305</fpage>
        <lpage>314</lpage>
        <pub-id pub-id-type="doi">10.2147/DDDT.S336643</pub-id>
      </element-citation>
    </ref>
    <ref id="CR5">
      <label>5.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Mohammed</surname>
            <given-names>H</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Progesterone receptor modulates ERalpha action in breast cancer</article-title>
        <source>Nature</source>
        <year>2015</year>
        <volume>523</volume>
        <issue>7560</issue>
        <fpage>313</fpage>
        <lpage>317</lpage>
        <pub-id pub-id-type="doi">10.1038/nature14583</pub-id>
        <?supplied-pmid 26153859?>
        <pub-id pub-id-type="pmid">26153859</pub-id>
      </element-citation>
    </ref>
    <ref id="CR6">
      <label>6.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Brisken</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Park</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Vass</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Lydon</surname>
            <given-names>JP</given-names>
          </name>
          <name>
            <surname>O'Malley</surname>
            <given-names>BW</given-names>
          </name>
          <name>
            <surname>Weinberg</surname>
            <given-names>RA</given-names>
          </name>
        </person-group>
        <article-title>A paracrine role for the epithelial progesterone receptor in mammary gland development</article-title>
        <source>Proc. Natl. Acad. Sci. USA</source>
        <year>1998</year>
        <volume>95</volume>
        <issue>9</issue>
        <fpage>5076</fpage>
        <lpage>5081</lpage>
        <pub-id pub-id-type="doi">10.1073/pnas.95.9.5076</pub-id>
        <?supplied-pmid 9560231?>
        <pub-id pub-id-type="pmid">9560231</pub-id>
      </element-citation>
    </ref>
    <ref id="CR7">
      <label>7.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Graham</surname>
            <given-names>JD</given-names>
          </name>
          <name>
            <surname>Clarke</surname>
            <given-names>CL</given-names>
          </name>
        </person-group>
        <article-title>Physiological action of progesterone in target tissues</article-title>
        <source>Endocr. Rev.</source>
        <year>1997</year>
        <volume>18</volume>
        <issue>4</issue>
        <fpage>502</fpage>
        <lpage>519</lpage>
        <pub-id pub-id-type="doi">10.1210/edrv.18.4.0308</pub-id>
        <?supplied-pmid 9267762?>
        <pub-id pub-id-type="pmid">9267762</pub-id>
      </element-citation>
    </ref>
    <ref id="CR8">
      <label>8.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Lydon</surname>
            <given-names>JP</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities</article-title>
        <source>Genes Dev.</source>
        <year>1995</year>
        <volume>9</volume>
        <issue>18</issue>
        <fpage>2266</fpage>
        <lpage>2278</lpage>
        <pub-id pub-id-type="doi">10.1101/gad.9.18.2266</pub-id>
        <?supplied-pmid 7557380?>
        <pub-id pub-id-type="pmid">7557380</pub-id>
      </element-citation>
    </ref>
    <ref id="CR9">
      <label>9.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Brisken</surname>
            <given-names>C</given-names>
          </name>
        </person-group>
        <article-title>Progesterone signalling in breast cancer: A neglected hormone coming into the limelight</article-title>
        <source>Nat. Rev. Cancer</source>
        <year>2013</year>
        <volume>13</volume>
        <issue>6</issue>
        <fpage>385</fpage>
        <lpage>396</lpage>
        <pub-id pub-id-type="doi">10.1038/nrc3518</pub-id>
        <?supplied-pmid 23702927?>
        <pub-id pub-id-type="pmid">23702927</pub-id>
      </element-citation>
    </ref>
    <ref id="CR10">
      <label>10.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ranjan</surname>
            <given-names>M</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Progesterone receptor antagonists reverse stem cell expansion and the paracrine effectors of progesterone action in the mouse mammary gland</article-title>
        <source>Breast Cancer Res.</source>
        <year>2021</year>
        <volume>23</volume>
        <issue>1</issue>
        <fpage>78</fpage>
        <pub-id pub-id-type="doi">10.1186/s13058-021-01455-2</pub-id>
        <?supplied-pmid 34344445?>
        <pub-id pub-id-type="pmid">34344445</pub-id>
      </element-citation>
    </ref>
    <ref id="CR11">
      <label>11.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Asselin-Labat</surname>
            <given-names>ML</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Control of mammary stem cell function by steroid hormone signalling</article-title>
        <source>Nature</source>
        <year>2010</year>
        <volume>465</volume>
        <issue>7299</issue>
        <fpage>798</fpage>
        <lpage>802</lpage>
        <pub-id pub-id-type="doi">10.1038/nature09027</pub-id>
        <?supplied-pmid 20383121?>
        <pub-id pub-id-type="pmid">20383121</pub-id>
      </element-citation>
    </ref>
    <ref id="CR12">
      <label>12.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Joshi</surname>
            <given-names>PA</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Progesterone induces adult mammary stem cell expansion</article-title>
        <source>Nature</source>
        <year>2010</year>
        <volume>465</volume>
        <issue>7299</issue>
        <fpage>803</fpage>
        <lpage>807</lpage>
        <pub-id pub-id-type="doi">10.1038/nature09091</pub-id>
        <?supplied-pmid 20445538?>
        <pub-id pub-id-type="pmid">20445538</pub-id>
      </element-citation>
    </ref>
    <ref id="CR13">
      <label>13.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Tomasetti</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Vogelstein</surname>
            <given-names>B</given-names>
          </name>
        </person-group>
        <article-title>Cancer etiology: Variation in cancer risk among tissues can be explained by the number of stem cell divisions</article-title>
        <source>Science</source>
        <year>2015</year>
        <volume>347</volume>
        <issue>6217</issue>
        <fpage>78</fpage>
        <lpage>81</lpage>
        <pub-id pub-id-type="doi">10.1126/science.1260825</pub-id>
        <?supplied-pmid 25554788?>
        <pub-id pub-id-type="pmid">25554788</pub-id>
      </element-citation>
    </ref>
    <ref id="CR14">
      <label>14.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Tomasetti</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Vogelstein</surname>
            <given-names>B</given-names>
          </name>
        </person-group>
        <article-title>Stem cell divisions, somatic mutations, cancer etiology, and cancer prevention</article-title>
        <source>Science</source>
        <year>2017</year>
        <volume>355</volume>
        <issue>6331</issue>
        <fpage>1330</fpage>
        <lpage>1334</lpage>
        <pub-id pub-id-type="doi">10.1126/science.aaf9011</pub-id>
        <?supplied-pmid 28336671?>
        <pub-id pub-id-type="pmid">28336671</pub-id>
      </element-citation>
    </ref>
    <ref id="CR15">
      <label>15.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Zheng</surname>
            <given-names>ZY</given-names>
          </name>
          <name>
            <surname>Bay</surname>
            <given-names>BH</given-names>
          </name>
          <name>
            <surname>Aw</surname>
            <given-names>SE</given-names>
          </name>
          <name>
            <surname>Lin</surname>
            <given-names>VC</given-names>
          </name>
        </person-group>
        <article-title>A novel antiestrogenic mechanism in progesterone receptor-transfected breast cancer cells</article-title>
        <source>J. Biol. Chem.</source>
        <year>2005</year>
        <volume>280</volume>
        <issue>17</issue>
        <fpage>17480</fpage>
        <lpage>17487</lpage>
        <pub-id pub-id-type="doi">10.1074/jbc.M501261200</pub-id>
        <?supplied-pmid 15728178?>
        <pub-id pub-id-type="pmid">15728178</pub-id>
      </element-citation>
    </ref>
    <ref id="CR16">
      <label>16.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Tomlinson</surname>
            <given-names>IP</given-names>
          </name>
          <name>
            <surname>Nicolai</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Solomon</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Bodmer</surname>
            <given-names>WF</given-names>
          </name>
        </person-group>
        <article-title>The frequency and mechanism of loss of heterozygosity on chromosome 11q in breast cancer</article-title>
        <source>J. Pathol.</source>
        <year>1996</year>
        <volume>180</volume>
        <issue>1</issue>
        <fpage>38</fpage>
        <lpage>43</lpage>
        <pub-id pub-id-type="doi">10.1002/(SICI)1096-9896(199609)180:1&lt;38::AID-PATH638&gt;3.0.CO;2-C</pub-id>
        <?supplied-pmid 8943813?>
        <pub-id pub-id-type="pmid">8943813</pub-id>
      </element-citation>
    </ref>
    <ref id="CR17">
      <label>17.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Cui</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Schiff</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Arpino</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Osborne</surname>
            <given-names>CK</given-names>
          </name>
          <name>
            <surname>Lee</surname>
            <given-names>AV</given-names>
          </name>
        </person-group>
        <article-title>Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy</article-title>
        <source>J. Clin. Oncol.</source>
        <year>2005</year>
        <volume>23</volume>
        <issue>30</issue>
        <fpage>7721</fpage>
        <lpage>7735</lpage>
        <pub-id pub-id-type="doi">10.1200/JCO.2005.09.004</pub-id>
        <?supplied-pmid 16234531?>
        <pub-id pub-id-type="pmid">16234531</pub-id>
      </element-citation>
    </ref>
    <ref id="CR18">
      <label>18.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Singhal</surname>
            <given-names>H</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Progesterone receptor isoforms, agonists and antagonists differentially reprogram estrogen signaling</article-title>
        <source>Oncotarget</source>
        <year>2018</year>
        <volume>9</volume>
        <issue>4</issue>
        <fpage>4282</fpage>
        <lpage>4300</lpage>
        <pub-id pub-id-type="doi">10.18632/oncotarget.21378</pub-id>
        <?supplied-pmid 29435103?>
        <pub-id pub-id-type="pmid">29435103</pub-id>
      </element-citation>
    </ref>
    <ref id="CR19">
      <label>19.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Lee</surname>
            <given-names>O</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Selective progesterone receptor modulators in early-stage breast cancer: A randomized, placebo-controlled phase II window-of-opportunity trial using telapristone acetate</article-title>
        <source>Clin. Cancer Res.</source>
        <year>2020</year>
        <volume>26</volume>
        <issue>1</issue>
        <fpage>25</fpage>
        <lpage>34</lpage>
        <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-19-0443</pub-id>
        <?supplied-pmid 31570566?>
        <pub-id pub-id-type="pmid">31570566</pub-id>
      </element-citation>
    </ref>
    <ref id="CR20">
      <label>20.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Afhuppe</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Sommer</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Muller</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Schwede</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Fuhrmann</surname>
            <given-names>U</given-names>
          </name>
          <name>
            <surname>Moller</surname>
            <given-names>C</given-names>
          </name>
        </person-group>
        <article-title>Global gene expression profiling of progesterone receptor modulators in T47D cells provides a new classification system</article-title>
        <source>J. Steroid. Biochem. Mol. Biol.</source>
        <year>2009</year>
        <volume>113</volume>
        <issue>1–2</issue>
        <fpage>105</fpage>
        <lpage>115</lpage>
        <pub-id pub-id-type="doi">10.1016/j.jsbmb.2008.11.015</pub-id>
        <?supplied-pmid 19130882?>
        <pub-id pub-id-type="pmid">19130882</pub-id>
      </element-citation>
    </ref>
    <ref id="CR21">
      <label>21.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Trabert</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Sherman</surname>
            <given-names>ME</given-names>
          </name>
          <name>
            <surname>Kannan</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Stanczyk</surname>
            <given-names>FZ</given-names>
          </name>
        </person-group>
        <article-title>Progesterone and breast cancer</article-title>
        <source>Endocr. Rev.</source>
        <year>2020</year>
        <volume>41</volume>
        <fpage>2</fpage>
        <pub-id pub-id-type="doi">10.1210/endrev/bnz001</pub-id>
      </element-citation>
    </ref>
    <ref id="CR22">
      <label>22.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Zheng</surname>
            <given-names>N</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Mifepristone inhibits ovarian cancer metastasis by intervening in SDF-1/CXCR4 chemokine axis</article-title>
        <source>Oncotarget</source>
        <year>2017</year>
        <volume>8</volume>
        <issue>35</issue>
        <fpage>59123</fpage>
        <lpage>59135</lpage>
        <pub-id pub-id-type="doi">10.18632/oncotarget.19289</pub-id>
        <?supplied-pmid 28938623?>
        <pub-id pub-id-type="pmid">28938623</pub-id>
      </element-citation>
    </ref>
    <ref id="CR23">
      <label>23.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ponikwicka-Tyszko</surname>
            <given-names>D</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Molecular mechanisms underlying mifepristone's agonistic action on ovarian cancer progression</article-title>
        <source>EBioMedicine</source>
        <year>2019</year>
        <volume>47</volume>
        <fpage>170</fpage>
        <lpage>183</lpage>
        <pub-id pub-id-type="doi">10.1016/j.ebiom.2019.08.035</pub-id>
        <?supplied-pmid 31466918?>
        <pub-id pub-id-type="pmid">31466918</pub-id>
      </element-citation>
    </ref>
    <ref id="CR24">
      <label>24.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ritch</surname>
            <given-names>SJ</given-names>
          </name>
          <name>
            <surname>Brandhagen</surname>
            <given-names>BN</given-names>
          </name>
          <name>
            <surname>Goyeneche</surname>
            <given-names>AA</given-names>
          </name>
          <name>
            <surname>Telleria</surname>
            <given-names>CM</given-names>
          </name>
        </person-group>
        <article-title>Advanced assessment of migration and invasion of cancer cells in response to mifepristone therapy using double fluorescence cytochemical labeling</article-title>
        <source>BMC Cancer</source>
        <year>2019</year>
        <volume>19</volume>
        <issue>1</issue>
        <fpage>376</fpage>
        <pub-id pub-id-type="doi">10.1186/s12885-019-5587-3</pub-id>
        <?supplied-pmid 31014286?>
        <pub-id pub-id-type="pmid">31014286</pub-id>
      </element-citation>
    </ref>
    <ref id="CR25">
      <label>25.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Tieszen</surname>
            <given-names>CR</given-names>
          </name>
          <name>
            <surname>Goyeneche</surname>
            <given-names>AA</given-names>
          </name>
          <name>
            <surname>Brandhagen</surname>
            <given-names>BN</given-names>
          </name>
          <name>
            <surname>Ortbahn</surname>
            <given-names>CT</given-names>
          </name>
          <name>
            <surname>Telleria</surname>
            <given-names>CM</given-names>
          </name>
        </person-group>
        <article-title>Antiprogestin mifepristone inhibits the growth of cancer cells of reproductive and non-reproductive origin regardless of progesterone receptor expression</article-title>
        <source>BMC Cancer</source>
        <year>2011</year>
        <volume>11</volume>
        <fpage>207</fpage>
        <pub-id pub-id-type="doi">10.1186/1471-2407-11-207</pub-id>
        <?supplied-pmid 21619605?>
        <pub-id pub-id-type="pmid">21619605</pub-id>
      </element-citation>
    </ref>
    <ref id="CR26">
      <label>26.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Rocereto</surname>
            <given-names>TF</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>A phase II evaluation of mifepristone in the treatment of recurrent or persistent epithelial ovarian, fallopian or primary peritoneal cancer: A gynecologic oncology group study</article-title>
        <source>Gynecol. Oncol.</source>
        <year>2010</year>
        <volume>116</volume>
        <issue>3</issue>
        <fpage>332</fpage>
        <lpage>334</lpage>
        <pub-id pub-id-type="doi">10.1016/j.ygyno.2009.10.071</pub-id>
        <?supplied-pmid 19922989?>
        <pub-id pub-id-type="pmid">19922989</pub-id>
      </element-citation>
    </ref>
    <ref id="CR27">
      <label>27.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Rolla</surname>
            <given-names>E</given-names>
          </name>
        </person-group>
        <article-title>Endometriosis: Advances and controversies in classification, pathogenesis, diagnosis, and treatment</article-title>
        <source>F1000 Res.</source>
        <year>2019</year>
        <volume>8</volume>
        <fpage>529</fpage>
        <pub-id pub-id-type="doi">10.12688/f1000research.14817.1</pub-id>
      </element-citation>
    </ref>
    <ref id="CR28">
      <label>28.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Lukes</surname>
            <given-names>AS</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Health-related quality of life with ulipristal acetate for treatment of uterine leiomyomas: A randomized controlled trial</article-title>
        <source>Obstet. Gynecol.</source>
        <year>2019</year>
        <volume>133</volume>
        <issue>5</issue>
        <fpage>869</fpage>
        <lpage>878</lpage>
        <pub-id pub-id-type="doi">10.1097/AOG.0000000000003211</pub-id>
        <?supplied-pmid 30969201?>
        <pub-id pub-id-type="pmid">30969201</pub-id>
      </element-citation>
    </ref>
    <ref id="CR29">
      <label>29.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Liu</surname>
            <given-names>JH</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Ulipristal acetate for treatment of uterine leiomyomas: A randomized controlled trial</article-title>
        <source>Obstet. Gynecol.</source>
        <year>2018</year>
        <volume>132</volume>
        <issue>5</issue>
        <fpage>1241</fpage>
        <lpage>1251</lpage>
        <pub-id pub-id-type="doi">10.1097/AOG.0000000000002942</pub-id>
        <?supplied-pmid 30303900?>
        <pub-id pub-id-type="pmid">30303900</pub-id>
      </element-citation>
    </ref>
    <ref id="CR30">
      <label>30.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Seitz</surname>
            <given-names>C</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Rationale and design of ASTEROID 2, a randomized, placebo- and active comparator-controlled study to assess the efficacy and safety of vilaprisan in patients with uterine fibroids</article-title>
        <source>Contemp. Clin. Trials</source>
        <year>2017</year>
        <volume>55</volume>
        <fpage>56</fpage>
        <lpage>62</lpage>
        <pub-id pub-id-type="doi">10.1016/j.cct.2017.02.002</pub-id>
        <?supplied-pmid 28185997?>
        <pub-id pub-id-type="pmid">28185997</pub-id>
      </element-citation>
    </ref>
    <ref id="CR31">
      <label>31.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ciebiera</surname>
            <given-names>M</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Vilaprisan, a new selective progesterone receptor modulator in uterine fibroid pharmacotherapy-will it really be a breakthrough?</article-title>
        <source>Curr. Pharm. Des.</source>
        <year>2020</year>
        <volume>26</volume>
        <issue>3</issue>
        <fpage>300</fpage>
        <lpage>309</lpage>
        <pub-id pub-id-type="doi">10.2174/1381612826666200127092208</pub-id>
        <?supplied-pmid 31985366?>
        <pub-id pub-id-type="pmid">31985366</pub-id>
      </element-citation>
    </ref>
    <ref id="CR32">
      <label>32.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Lewis</surname>
            <given-names>JH</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Onapristone extended release: Safety evaluation from phase I–II studies with an emphasis on hepatotoxicity</article-title>
        <source>Drug Saf.</source>
        <year>2020</year>
        <volume>43</volume>
        <issue>10</issue>
        <fpage>1045</fpage>
        <lpage>1055</lpage>
        <pub-id pub-id-type="doi">10.1007/s40264-020-00964-x</pub-id>
        <?supplied-pmid 32594454?>
        <pub-id pub-id-type="pmid">32594454</pub-id>
      </element-citation>
    </ref>
    <ref id="CR33">
      <label>33.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>So</surname>
            <given-names>SS</given-names>
          </name>
          <name>
            <surname>van Helden</surname>
            <given-names>SP</given-names>
          </name>
          <name>
            <surname>van Geerestein</surname>
            <given-names>VJ</given-names>
          </name>
          <name>
            <surname>Karplus</surname>
            <given-names>M</given-names>
          </name>
        </person-group>
        <article-title>Quantitative structure-activity relationship studies of progesterone receptor binding steroids</article-title>
        <source>J. Chem. Inf. Comput. Sci.</source>
        <year>2000</year>
        <volume>40</volume>
        <issue>3</issue>
        <fpage>762</fpage>
        <lpage>772</lpage>
        <pub-id pub-id-type="doi">10.1021/ci990130v</pub-id>
        <?supplied-pmid 10850780?>
        <pub-id pub-id-type="pmid">10850780</pub-id>
      </element-citation>
    </ref>
    <ref id="CR34">
      <label>34.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Khadijah Saghiri</surname>
            <given-names>ID</given-names>
          </name>
          <name>
            <surname>Melkemi</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Mesli</surname>
            <given-names>F</given-names>
          </name>
        </person-group>
        <article-title>QSAR study, molecular docking/dynamics simulations and ADME prediction of 2-phenyl-1H-indole derivatives as potential breast cancer inhibitors</article-title>
        <source>Biointerface Res. Appl. Chem.</source>
        <year>2022</year>
        <volume>13</volume>
        <issue>2</issue>
        <fpage>154</fpage>
        <pub-id pub-id-type="doi">10.33263/BRIAC132.154</pub-id>
      </element-citation>
    </ref>
    <ref id="CR35">
      <label>35.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Soderholm</surname>
            <given-names>AA</given-names>
          </name>
          <name>
            <surname>Lehtovuori</surname>
            <given-names>PT</given-names>
          </name>
          <name>
            <surname>Nyronen</surname>
            <given-names>TH</given-names>
          </name>
        </person-group>
        <article-title>Docking and three-dimensional quantitative structure-activity relationship (3D QSAR) analyses of nonsteroidal progesterone receptor ligands</article-title>
        <source>J. Med. Chem.</source>
        <year>2006</year>
        <volume>49</volume>
        <issue>14</issue>
        <fpage>4261</fpage>
        <lpage>4268</lpage>
        <pub-id pub-id-type="doi">10.1021/jm060234e</pub-id>
        <?supplied-pmid 16821785?>
        <pub-id pub-id-type="pmid">16821785</pub-id>
      </element-citation>
    </ref>
    <ref id="CR36">
      <label>36.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Jones</surname>
            <given-names>DG</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Discovery of non-steroidal mifepristone mimetics: pyrazoline-based PR antagonists</article-title>
        <source>Bioorg. Med. Chem. Lett.</source>
        <year>2005</year>
        <volume>15</volume>
        <issue>13</issue>
        <fpage>3203</fpage>
        <lpage>3206</lpage>
        <pub-id pub-id-type="doi">10.1016/j.bmcl.2005.05.001</pub-id>
        <?supplied-pmid 15925510?>
        <pub-id pub-id-type="pmid">15925510</pub-id>
      </element-citation>
    </ref>
    <ref id="CR37">
      <label>37.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Du</surname>
            <given-names>Y</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Aromatic beta-amino-ketone derivatives as novel selective non-steroidal progesterone receptor antagonists</article-title>
        <source>Bioorg. Med. Chem.</source>
        <year>2010</year>
        <volume>18</volume>
        <issue>12</issue>
        <fpage>4255</fpage>
        <lpage>4268</lpage>
        <pub-id pub-id-type="doi">10.1016/j.bmc.2010.04.092</pub-id>
        <?supplied-pmid 20510622?>
        <pub-id pub-id-type="pmid">20510622</pub-id>
      </element-citation>
    </ref>
    <ref id="CR38">
      <label>38.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Matsuzaka</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Uesawa</surname>
            <given-names>Y</given-names>
          </name>
        </person-group>
        <article-title>DeepSnap-deep learning approach predicts progesterone receptor antagonist activity with high performance</article-title>
        <source>Front. Bioeng. Biotechnol.</source>
        <year>2019</year>
        <volume>7</volume>
        <fpage>485</fpage>
        <pub-id pub-id-type="doi">10.3389/fbioe.2019.00485</pub-id>
        <?supplied-pmid 32039185?>
        <pub-id pub-id-type="pmid">32039185</pub-id>
      </element-citation>
    </ref>
    <ref id="CR39">
      <label>39.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Mendez</surname>
            <given-names>D</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>ChEMBL: Towards direct deposition of bioassay data</article-title>
        <source>Nucleic Acids Res.</source>
        <year>2019</year>
        <volume>47</volume>
        <issue>D1</issue>
        <fpage>D930</fpage>
        <lpage>D940</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gky1075</pub-id>
        <?supplied-pmid 30398643?>
        <pub-id pub-id-type="pmid">30398643</pub-id>
      </element-citation>
    </ref>
    <ref id="CR40">
      <label>40.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Aykul</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Martinez-Hackert</surname>
            <given-names>E</given-names>
          </name>
        </person-group>
        <article-title>Determination of half-maximal inhibitory concentration using biosensor-based protein interaction analysis</article-title>
        <source>Anal. Biochem.</source>
        <year>2016</year>
        <volume>508</volume>
        <fpage>97</fpage>
        <lpage>103</lpage>
        <pub-id pub-id-type="doi">10.1016/j.ab.2016.06.025</pub-id>
        <?supplied-pmid 27365221?>
        <pub-id pub-id-type="pmid">27365221</pub-id>
      </element-citation>
    </ref>
    <ref id="CR41">
      <label>41.</label>
      <mixed-citation publication-type="other">Beck, C. Y. <italic>et al</italic>. Assay operations for SAR support. in <italic>Assay Guidance Manual</italic> (Eli Lilly &amp; Company and the National Center for Advancing Translational Sciences, 2017). <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK91994/?report">https://www.ncbi.nlm.nih.gov/books/NBK91994/?report</ext-link>.</mixed-citation>
    </ref>
    <ref id="CR42">
      <label>42.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Carta</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Onnis</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Knox</surname>
            <given-names>AJ</given-names>
          </name>
          <name>
            <surname>Fayne</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Lloyd</surname>
            <given-names>DG</given-names>
          </name>
        </person-group>
        <article-title>Permuting input for more effective sampling of 3D conformer space</article-title>
        <source>J. Comput. Aid. Mol. Des.</source>
        <year>2006</year>
        <volume>20</volume>
        <issue>3</issue>
        <fpage>179</fpage>
        <lpage>190</lpage>
        <pub-id pub-id-type="doi">10.1007/s10822-006-9044-4</pub-id>
      </element-citation>
    </ref>
    <ref id="CR43">
      <label>43.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Su</surname>
            <given-names>Z-D</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>iLoc-lncRNA: Predict the subcellular location of lncRNAs by incorporating octamer composition into general PseKNC</article-title>
        <source>Bioinformatics</source>
        <year>2018</year>
        <volume>34</volume>
        <issue>24</issue>
        <fpage>4196</fpage>
        <lpage>4204</lpage>
        <?supplied-pmid 29931187?>
        <pub-id pub-id-type="pmid">29931187</pub-id>
      </element-citation>
    </ref>
    <ref id="CR44">
      <label>44.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Rao</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Zhou</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Su</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Wei</surname>
            <given-names>L</given-names>
          </name>
        </person-group>
        <article-title>ACPred-Fuse: Fusing multi-view information improves the prediction of anticancer peptides</article-title>
        <source>Brief. Bioinform.</source>
        <year>2020</year>
        <volume>21</volume>
        <issue>5</issue>
        <fpage>1846</fpage>
        <lpage>1855</lpage>
        <pub-id pub-id-type="doi">10.1093/bib/bbz088</pub-id>
        <pub-id pub-id-type="pmid">31729528</pub-id>
      </element-citation>
    </ref>
    <ref id="CR45">
      <label>45.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Qiang</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Zhou</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Ye</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Du</surname>
            <given-names>P-F</given-names>
          </name>
          <name>
            <surname>Su</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Wei</surname>
            <given-names>L</given-names>
          </name>
        </person-group>
        <article-title>CPPred-FL: A sequence-based predictor for large-scale identification of cell-penetrating peptides by feature representation learning</article-title>
        <source>Brief. Bioinform.</source>
        <year>2020</year>
        <volume>21</volume>
        <issue>1</issue>
        <fpage>11</fpage>
        <lpage>23</lpage>
      </element-citation>
    </ref>
    <ref id="CR46">
      <label>46.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Charoenkwan</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Nantasenamat</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Hasan</surname>
            <given-names>MM</given-names>
          </name>
          <name>
            <surname>Moni</surname>
            <given-names>MA</given-names>
          </name>
          <name>
            <surname>Manavalan</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Shoombuatong</surname>
            <given-names>W</given-names>
          </name>
        </person-group>
        <article-title>StackDPPIV: A novel computational approach for accurate prediction of dipeptidyl peptidase IV (DPP-IV) inhibitory peptides</article-title>
        <source>Methods</source>
        <year>2021</year>
        <volume>204</volume>
        <fpage>189</fpage>
        <lpage>198</lpage>
        <pub-id pub-id-type="doi">10.1016/j.ymeth.2021.12.001</pub-id>
        <pub-id pub-id-type="pmid">34883239</pub-id>
      </element-citation>
    </ref>
    <ref id="CR47">
      <label>47.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Charoenkwan</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Chiangjong</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Nantasenamat</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Hasan</surname>
            <given-names>MM</given-names>
          </name>
          <name>
            <surname>Manavalan</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Shoombuatong</surname>
            <given-names>W</given-names>
          </name>
        </person-group>
        <article-title>StackIL6: A stacking ensemble model for improving the prediction of IL-6 inducing peptides</article-title>
        <source>Brief. Bioinform.</source>
        <year>2021</year>
        <volume>22</volume>
        <issue>6</issue>
        <fpage>172</fpage>
        <pub-id pub-id-type="doi">10.1093/bib/bbab172</pub-id>
      </element-citation>
    </ref>
    <ref id="CR48">
      <label>48.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Malik</surname>
            <given-names>AA</given-names>
          </name>
          <name>
            <surname>Chotpatiwetchkul</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Phanus-Umporn</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Nantasenamat</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Charoenkwan</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Shoombuatong</surname>
            <given-names>W</given-names>
          </name>
        </person-group>
        <article-title>StackHCV: A web-based integrative machine-learning framework for large-scale identification of hepatitis C virus NS5B inhibitors</article-title>
        <source>J. Comput. Aid. Mol. Des.</source>
        <year>2021</year>
        <volume>35</volume>
        <issue>10</issue>
        <fpage>1037</fpage>
        <lpage>1053</lpage>
        <pub-id pub-id-type="doi">10.1007/s10822-021-00418-1</pub-id>
      </element-citation>
    </ref>
    <ref id="CR49">
      <label>49.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Fu</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Cai</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Zeng</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Zou</surname>
            <given-names>Q</given-names>
          </name>
        </person-group>
        <article-title>StackCPPred: A stacking and pairwise energy content-based prediction of cell-penetrating peptides and their uptake efficiency</article-title>
        <source>Bioinformatics</source>
        <year>2020</year>
        <volume>36</volume>
        <issue>10</issue>
        <fpage>3028</fpage>
        <lpage>3034</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/btaa131</pub-id>
        <pub-id pub-id-type="pmid">32105326</pub-id>
      </element-citation>
    </ref>
    <ref id="CR50">
      <label>50.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Mishra</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Pokhrel</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Hoque</surname>
            <given-names>MT</given-names>
          </name>
        </person-group>
        <article-title>StackDPPred: A stacking based prediction of DNA-binding protein from sequence</article-title>
        <source>Bioinformatics</source>
        <year>2019</year>
        <volume>35</volume>
        <issue>3</issue>
        <fpage>433</fpage>
        <lpage>441</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/bty653</pub-id>
        <pub-id pub-id-type="pmid">30032213</pub-id>
      </element-citation>
    </ref>
    <ref id="CR51">
      <label>51.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Pedregosa</surname>
            <given-names>F</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Scikit-learn: Machine learning in Python</article-title>
        <source>J. Mach. Learn. Res.</source>
        <year>2011</year>
        <volume>12</volume>
        <fpage>2825</fpage>
        <lpage>2830</lpage>
      </element-citation>
    </ref>
    <ref id="CR52">
      <label>52.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Charoenkwan</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Schaduangrat</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Nantasenamat</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Piacham</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Shoombuatong</surname>
            <given-names>W</given-names>
          </name>
        </person-group>
        <article-title>iQSP: A sequence-based tool for the prediction and analysis of quorum sensing peptides via Chou’s 5-steps rule and informative physicochemical properties</article-title>
        <source>Int. J. Mol. Sci.</source>
        <year>2020</year>
        <volume>21</volume>
        <issue>1</issue>
        <fpage>75</fpage>
        <pub-id pub-id-type="doi">10.3390/ijms21010075</pub-id>
      </element-citation>
    </ref>
    <ref id="CR53">
      <label>53.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Azadpour</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>McKay</surname>
            <given-names>CM</given-names>
          </name>
          <name>
            <surname>Smith</surname>
            <given-names>RL</given-names>
          </name>
        </person-group>
        <article-title>Estimating confidence intervals for information transfer analysis of confusion matrices</article-title>
        <source>J. Acoust. Soc. Am.</source>
        <year>2014</year>
        <volume>135</volume>
        <issue>3</issue>
        <fpage>140</fpage>
        <lpage>146</lpage>
        <pub-id pub-id-type="doi">10.1121/1.4865840</pub-id>
      </element-citation>
    </ref>
    <ref id="CR54">
      <label>54.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Charoenkwan</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Anuwongcharoen</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Nantasenamat</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Hasan</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Shoombuatong</surname>
            <given-names>W</given-names>
          </name>
        </person-group>
        <article-title>In silico approaches for the prediction and analysis of antiviral peptides: A review</article-title>
        <source>Curr. Pharm. Des.</source>
        <year>2021</year>
        <volume>27</volume>
        <fpage>2180</fpage>
        <lpage>2188</lpage>
        <pub-id pub-id-type="doi">10.2174/1381612826666201102105827</pub-id>
        <pub-id pub-id-type="pmid">33138759</pub-id>
      </element-citation>
    </ref>
    <ref id="CR55">
      <label>55.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Charoenkwan</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Chiangjong</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Hasan</surname>
            <given-names>MM</given-names>
          </name>
          <name>
            <surname>Nantasenamat</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Shoombuatong</surname>
            <given-names>W</given-names>
          </name>
        </person-group>
        <article-title>Review and comparative analysis of machine learning-based predictors for predicting and analyzing anti-angiogenic peptides</article-title>
        <source>Curr. Med. Chem.</source>
        <year>2022</year>
        <volume>29</volume>
        <fpage>849</fpage>
        <lpage>864</lpage>
        <pub-id pub-id-type="doi">10.2174/0929867328666210810145806</pub-id>
        <pub-id pub-id-type="pmid">34375178</pub-id>
      </element-citation>
    </ref>
    <ref id="CR56">
      <label>56.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Dao</surname>
            <given-names>F-Y</given-names>
          </name>
          <name>
            <surname>Lv</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>Z-M</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Lin</surname>
            <given-names>H</given-names>
          </name>
        </person-group>
        <article-title>DeepYY1: A deep learning approach to identify YY1-mediated chromatin loops</article-title>
        <source>Brief. Bioinform.</source>
        <year>2021</year>
        <volume>22</volume>
        <issue>4</issue>
        <fpage>356</fpage>
        <pub-id pub-id-type="doi">10.1093/bib/bbaa356</pub-id>
      </element-citation>
    </ref>
    <ref id="CR57">
      <label>57.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Yang</surname>
            <given-names>H</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>A comparison and assessment of computational method for identifying recombination hotspots in Saccharomyces cerevisiae</article-title>
        <source>Brief. Bioinform.</source>
        <year>2020</year>
        <volume>21</volume>
        <issue>5</issue>
        <fpage>1568</fpage>
        <lpage>1580</lpage>
        <pub-id pub-id-type="doi">10.1093/bib/bbz123</pub-id>
        <pub-id pub-id-type="pmid">31633777</pub-id>
      </element-citation>
    </ref>
    <ref id="CR58">
      <label>58.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Dao</surname>
            <given-names>F-Y</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Identify origin of replication in <italic>Saccharomyces cerevisiae</italic> using two-step feature selection technique</article-title>
        <source>Bioinformatics</source>
        <year>2019</year>
        <volume>35</volume>
        <issue>12</issue>
        <fpage>2075</fpage>
        <lpage>2083</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/bty943</pub-id>
        <pub-id pub-id-type="pmid">30428009</pub-id>
      </element-citation>
    </ref>
    <ref id="CR59">
      <label>59.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Chen</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Lv</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Nie</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Lin</surname>
            <given-names>H</given-names>
          </name>
        </person-group>
        <article-title>i6mA-Pred: Identifying DNA N6-methyladenine sites in the rice genome</article-title>
        <source>Bioinformatics</source>
        <year>2019</year>
        <volume>35</volume>
        <issue>16</issue>
        <fpage>2796</fpage>
        <lpage>2800</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/btz015</pub-id>
        <pub-id pub-id-type="pmid">30624619</pub-id>
      </element-citation>
    </ref>
    <ref id="CR60">
      <label>60.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Lv</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Dao</surname>
            <given-names>F-Y</given-names>
          </name>
          <name>
            <surname>Guan</surname>
            <given-names>Z-X</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>Y-W</given-names>
          </name>
          <name>
            <surname>Lin</surname>
            <given-names>H</given-names>
          </name>
        </person-group>
        <article-title>Deep-Kcr: Accurate detection of lysine crotonylation sites using deep learning method</article-title>
        <source>Brief. Bioinform.</source>
        <year>2021</year>
        <volume>22</volume>
        <issue>4</issue>
        <fpage>255</fpage>
        <pub-id pub-id-type="doi">10.1093/bib/bbaa255</pub-id>
      </element-citation>
    </ref>
    <ref id="CR61">
      <label>61.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Xu</surname>
            <given-names>Z-C</given-names>
          </name>
          <name>
            <surname>Feng</surname>
            <given-names>P-M</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Qiu</surname>
            <given-names>W-R</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Lin</surname>
            <given-names>H</given-names>
          </name>
        </person-group>
        <article-title>iRNAD: A computational tool for identifying D modification sites in RNA sequence</article-title>
        <source>Bioinformatics</source>
        <year>2019</year>
        <volume>35</volume>
        <issue>23</issue>
        <fpage>4922</fpage>
        <lpage>4929</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/btz358</pub-id>
        <pub-id pub-id-type="pmid">31077296</pub-id>
      </element-citation>
    </ref>
    <ref id="CR62">
      <label>62.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>O'Boyle</surname>
            <given-names>NM</given-names>
          </name>
          <name>
            <surname>Banck</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>James</surname>
            <given-names>CA</given-names>
          </name>
          <name>
            <surname>Morley</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Vandermeersch</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Hutchison</surname>
            <given-names>GR</given-names>
          </name>
        </person-group>
        <article-title>Open Babel: An open chemical toolbox</article-title>
        <source>J. Cheminform.</source>
        <year>2011</year>
        <volume>3</volume>
        <fpage>33</fpage>
        <pub-id pub-id-type="doi">10.1186/1758-2946-3-33</pub-id>
        <?supplied-pmid 21982300?>
        <pub-id pub-id-type="pmid">21982300</pub-id>
      </element-citation>
    </ref>
    <ref id="CR63">
      <label>63.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Burley</surname>
            <given-names>SK</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>RCSB Protein Data Bank: Powerful new tools for exploring 3D structures of biological macromolecules for basic and applied research and education in fundamental biology, biomedicine, biotechnology, bioengineering and energy sciences</article-title>
        <source>Nucleic Acids Res.</source>
        <year>2021</year>
        <volume>49</volume>
        <issue>D1</issue>
        <fpage>D437</fpage>
        <lpage>D451</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkaa1038</pub-id>
        <?supplied-pmid 33211854?>
        <pub-id pub-id-type="pmid">33211854</pub-id>
      </element-citation>
    </ref>
    <ref id="CR64">
      <label>64.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Morris</surname>
            <given-names>GM</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility</article-title>
        <source>J. Comput. Chem.</source>
        <year>2009</year>
        <volume>30</volume>
        <issue>16</issue>
        <fpage>2785</fpage>
        <lpage>2791</lpage>
        <pub-id pub-id-type="doi">10.1002/jcc.21256</pub-id>
        <?supplied-pmid 19399780?>
        <pub-id pub-id-type="pmid">19399780</pub-id>
      </element-citation>
    </ref>
    <ref id="CR65">
      <label>65.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Trott</surname>
            <given-names>O</given-names>
          </name>
          <name>
            <surname>Olson</surname>
            <given-names>AJ</given-names>
          </name>
        </person-group>
        <article-title>AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading</article-title>
        <source>J. Comput. Chem.</source>
        <year>2010</year>
        <volume>31</volume>
        <issue>2</issue>
        <fpage>455</fpage>
        <lpage>461</lpage>
        <pub-id pub-id-type="doi">10.1002/jcc.21334</pub-id>
        <?supplied-pmid 19499576?>
        <pub-id pub-id-type="pmid">19499576</pub-id>
      </element-citation>
    </ref>
    <ref id="CR66">
      <label>66.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Eberhardt</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Santos-Martins</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Tillack</surname>
            <given-names>AF</given-names>
          </name>
          <name>
            <surname>Forli</surname>
            <given-names>S</given-names>
          </name>
        </person-group>
        <article-title>AutoDock Vina 1.2.0: New docking methods, expanded force field, and python bindings</article-title>
        <source>J. Chem. Inf. Model</source>
        <year>2021</year>
        <volume>61</volume>
        <issue>8</issue>
        <fpage>3891</fpage>
        <lpage>3898</lpage>
        <pub-id pub-id-type="doi">10.1021/acs.jcim.1c00203</pub-id>
        <?supplied-pmid 34278794?>
        <pub-id pub-id-type="pmid">34278794</pub-id>
      </element-citation>
    </ref>
    <ref id="CR67">
      <label>67.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Xie</surname>
            <given-names>R</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>DeepVF: A deep learning-based hybrid framework for identifying virulence factors using the stacking strategy</article-title>
        <source>Brief. Bioinform.</source>
        <year>2021</year>
        <volume>22</volume>
        <issue>3</issue>
        <fpage>125</fpage>
        <pub-id pub-id-type="doi">10.1093/bib/bbaa125</pub-id>
      </element-citation>
    </ref>
    <ref id="CR68">
      <label>68.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Van Der Maaten</surname>
            <given-names>L</given-names>
          </name>
        </person-group>
        <article-title>Accelerating t-SNE using tree-based algorithms</article-title>
        <source>J. Mach. Learn. Res.</source>
        <year>2014</year>
        <volume>15</volume>
        <issue>1</issue>
        <fpage>3221</fpage>
        <lpage>3245</lpage>
      </element-citation>
    </ref>
    <ref id="CR69">
      <label>69.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Van der Maaten</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Hinton</surname>
            <given-names>G</given-names>
          </name>
        </person-group>
        <article-title>Visualizing data using t-SNE</article-title>
        <source>J. Mach. Learn. Res.</source>
        <year>2008</year>
        <volume>9</volume>
        <fpage>11</fpage>
      </element-citation>
    </ref>
    <ref id="CR70">
      <label>70.</label>
      <mixed-citation publication-type="other">Lee, S. M. L. A. S.-I. <italic>A Unified Approach to Interpreting Model Predictions</italic>. Proceeding (2017).</mixed-citation>
    </ref>
    <ref id="CR71">
      <label>71.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kumar</surname>
            <given-names>R</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>The dynamic structure of the estrogen receptor</article-title>
        <source>J. Amino Acids</source>
        <year>2011</year>
        <volume>2011</volume>
        <fpage>812540</fpage>
        <pub-id pub-id-type="doi">10.4061/2011/812540</pub-id>
        <?supplied-pmid 22312471?>
        <pub-id pub-id-type="pmid">22312471</pub-id>
      </element-citation>
    </ref>
    <ref id="CR72">
      <label>72.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Moller</surname>
            <given-names>C</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Discovery of vilaprisan (BAY 1002670): A highly potent and selective progesterone receptor modulator optimized for gynecologic therapies</article-title>
        <source>ChemMedChem</source>
        <year>2018</year>
        <volume>13</volume>
        <issue>21</issue>
        <fpage>2271</fpage>
        <lpage>2280</lpage>
        <pub-id pub-id-type="doi">10.1002/cmdc.201800487</pub-id>
        <?supplied-pmid 30407750?>
        <pub-id pub-id-type="pmid">30407750</pub-id>
      </element-citation>
    </ref>
    <ref id="CR73">
      <label>73.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Jin</surname>
            <given-names>C</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Synthesis and identification of novel 11beta-aryl-4',5'-dihydrospiro[estra-4,9-diene-17beta,4'-oxazole] analogs with dissociated antiprogesterone activities</article-title>
        <source>Bioorg. Med. Chem. Lett.</source>
        <year>2007</year>
        <volume>17</volume>
        <issue>21</issue>
        <fpage>5754</fpage>
        <lpage>5757</lpage>
        <pub-id pub-id-type="doi">10.1016/j.bmcl.2007.08.064</pub-id>
        <?supplied-pmid 17855092?>
        <pub-id pub-id-type="pmid">17855092</pub-id>
      </element-citation>
    </ref>
    <ref id="CR74">
      <label>74.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Nishiyama</surname>
            <given-names>Y</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Novel nonsteroidal progesterone receptor (PR) antagonists with a phenanthridinone skeleton</article-title>
        <source>ACS Med. Chem. Lett.</source>
        <year>2018</year>
        <volume>9</volume>
        <issue>7</issue>
        <fpage>641</fpage>
        <lpage>645</lpage>
        <pub-id pub-id-type="doi">10.1021/acsmedchemlett.8b00058</pub-id>
        <?supplied-pmid 30034593?>
        <pub-id pub-id-type="pmid">30034593</pub-id>
      </element-citation>
    </ref>
    <ref id="CR75">
      <label>75.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Spitz</surname>
            <given-names>IM</given-names>
          </name>
        </person-group>
        <article-title>Progesterone receptor antagonists</article-title>
        <source>Curr. Opin. Investig. Drugs</source>
        <year>2006</year>
        <volume>7</volume>
        <issue>10</issue>
        <fpage>882</fpage>
        <lpage>890</lpage>
        <?supplied-pmid 17086932?>
        <pub-id pub-id-type="pmid">17086932</pub-id>
      </element-citation>
    </ref>
    <ref id="CR76">
      <label>76.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Richardson</surname>
            <given-names>TI</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Novel 3-aryl indoles as progesterone receptor antagonists for uterine fibroids</article-title>
        <source>ACS Med. Chem. Lett.</source>
        <year>2011</year>
        <volume>2</volume>
        <issue>2</issue>
        <fpage>148</fpage>
        <lpage>153</lpage>
        <pub-id pub-id-type="doi">10.1021/ml100220b</pub-id>
        <?supplied-pmid 24900294?>
        <pub-id pub-id-type="pmid">24900294</pub-id>
      </element-citation>
    </ref>
    <ref id="CR77">
      <label>77.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Greaves</surname>
            <given-names>RF</given-names>
          </name>
          <name>
            <surname>Jevalikar</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Hewitt</surname>
            <given-names>JK</given-names>
          </name>
          <name>
            <surname>Zacharin</surname>
            <given-names>MR</given-names>
          </name>
        </person-group>
        <article-title>A guide to understanding the steroid pathway: New insights and diagnostic implications</article-title>
        <source>Clin. Biochem.</source>
        <year>2014</year>
        <volume>47</volume>
        <issue>15</issue>
        <fpage>5</fpage>
        <lpage>15</lpage>
        <pub-id pub-id-type="doi">10.1016/j.clinbiochem.2014.07.017</pub-id>
        <?supplied-pmid 25086367?>
        <pub-id pub-id-type="pmid">25086367</pub-id>
      </element-citation>
    </ref>
    <ref id="CR78">
      <label>78.</label>
      <mixed-citation publication-type="other">Lala, T. H. D. <italic>et al</italic>. <italic>Abstract P6-20-13: The Pure Progesterone Receptor (PR) Antagonist Onapristone Enhances the Anti-Proliferative Effects of CDK4/6 Inhibitors in Preclinical in-Vitro Breast Cancer Models</italic>. (American Association for Cancer Research, Proceeding, 2019).</mixed-citation>
    </ref>
    <ref id="CR79">
      <label>79.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Islam</surname>
            <given-names>MS</given-names>
          </name>
          <name>
            <surname>Afrin</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Jones</surname>
            <given-names>SI</given-names>
          </name>
          <name>
            <surname>Segars</surname>
            <given-names>J</given-names>
          </name>
        </person-group>
        <article-title>Selective progesterone receptor modulators-mechanisms and therapeutic utility</article-title>
        <source>Endocr. Rev.</source>
        <year>2020</year>
        <volume>41</volume>
        <fpage>5</fpage>
        <pub-id pub-id-type="doi">10.1210/endrev/bnaa012</pub-id>
      </element-citation>
    </ref>
    <ref id="CR80">
      <label>80.</label>
      <element-citation publication-type="book">
        <person-group person-group-type="author">
          <name>
            <surname>MichaelLewis</surname>
            <given-names>CB</given-names>
          </name>
          <name>
            <surname>Hardebeck</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Wireduaah</surname>
            <given-names>S</given-names>
          </name>
        </person-group>
        <person-group person-group-type="editor">
          <name>
            <surname>Hof</surname>
            <given-names>DWJAF</given-names>
          </name>
        </person-group>
        <article-title>Modern computational approaches to understanding interactions of aromatics</article-title>
        <source>Aromatic interactions: frontiers in knowledge and application</source>
        <year>2017</year>
        <publisher-name>Royal Society of Chemistry</publisher-name>
      </element-citation>
    </ref>
    <ref id="CR81">
      <label>81.</label>
      <mixed-citation publication-type="other">N. C. F. B. Information. <italic>PubChem Compound Summary for CID 44451278</italic>. <ext-link ext-link-type="uri" xlink:href="https://pubchem.ncbi.nlm.nih.gov/compound/44451278">https://pubchem.ncbi.nlm.nih.gov/compound/44451278</ext-link>. Accessed 15 June 2022.</mixed-citation>
    </ref>
    <ref id="CR82">
      <label>82.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Rewinkel</surname>
            <given-names>J</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>11-(pyridinylphenyl)steroids: A new class of mixed-profile progesterone agonists/antagonists</article-title>
        <source>Bioorg. Med. Chem.</source>
        <year>2008</year>
        <volume>16</volume>
        <issue>6</issue>
        <fpage>2753</fpage>
        <lpage>2763</lpage>
        <pub-id pub-id-type="doi">10.1016/j.bmc.2008.01.010</pub-id>
        <?supplied-pmid 18243712?>
        <pub-id pub-id-type="pmid">18243712</pub-id>
      </element-citation>
    </ref>
    <ref id="CR83">
      <label>83.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Nickisch</surname>
            <given-names>K</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Synthesis and biological evaluation of partially fluorinated antiprogestins and mesoprogestins</article-title>
        <source>Steroids</source>
        <year>2013</year>
        <volume>78</volume>
        <issue>2</issue>
        <fpage>255</fpage>
        <lpage>267</lpage>
        <pub-id pub-id-type="doi">10.1016/j.steroids.2012.09.010</pub-id>
        <?supplied-pmid 23178161?>
        <pub-id pub-id-type="pmid">23178161</pub-id>
      </element-citation>
    </ref>
    <ref id="CR84">
      <label>84.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Nickisch</surname>
            <given-names>K</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Synthesis and biological evaluation of 11' imidazolyl antiprogestins and mesoprogestins</article-title>
        <source>Steroids</source>
        <year>2014</year>
        <volume>92</volume>
        <fpage>45</fpage>
        <lpage>55</lpage>
        <pub-id pub-id-type="doi">10.1016/j.steroids.2014.08.017</pub-id>
        <?supplied-pmid 25174783?>
        <pub-id pub-id-type="pmid">25174783</pub-id>
      </element-citation>
    </ref>
    <ref id="CR85">
      <label>85.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Qingxin Cui</surname>
            <given-names>RB</given-names>
          </name>
          <name>
            <surname>Xu</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>Q</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Bian</surname>
            <given-names>Q</given-names>
          </name>
        </person-group>
        <article-title>New molecular entities and structure–activity relationships of drugs designed by the natural product derivatization method from 2010 to 2018 author links open overlay panel</article-title>
        <source>Stud. Nat. Prod. Chem.</source>
        <year>2021</year>
        <volume>69</volume>
        <fpage>371</fpage>
        <lpage>415</lpage>
        <pub-id pub-id-type="doi">10.1016/B978-0-12-819487-4.00016-1</pub-id>
      </element-citation>
    </ref>
    <ref id="CR86">
      <label>86.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kang</surname>
            <given-names>FA</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Parallel synthesis and SAR study of novel oxa-steroids as potent and selective progesterone receptor antagonists</article-title>
        <source>Bioorg. Med. Chem. Lett.</source>
        <year>2007</year>
        <volume>17</volume>
        <issue>9</issue>
        <fpage>2531</fpage>
        <lpage>2534</lpage>
        <pub-id pub-id-type="doi">10.1016/j.bmcl.2007.02.013</pub-id>
        <?supplied-pmid 17317167?>
        <pub-id pub-id-type="pmid">17317167</pub-id>
      </element-citation>
    </ref>
    <ref id="CR87">
      <label>87.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Winneker</surname>
            <given-names>RC</given-names>
          </name>
          <name>
            <surname>Fensome</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Yudt</surname>
            <given-names>MR</given-names>
          </name>
          <name>
            <surname>McComas</surname>
            <given-names>CC</given-names>
          </name>
          <name>
            <surname>Unwalla</surname>
            <given-names>RJ</given-names>
          </name>
        </person-group>
        <article-title>A new generation of progesterone receptor modulators</article-title>
        <source>Steroids</source>
        <year>2008</year>
        <volume>73</volume>
        <issue>7</issue>
        <fpage>689</fpage>
        <lpage>701</lpage>
        <pub-id pub-id-type="doi">10.1016/j.steroids.2008.03.005</pub-id>
        <?supplied-pmid 18472121?>
        <pub-id pub-id-type="pmid">18472121</pub-id>
      </element-citation>
    </ref>
    <ref id="CR88">
      <label>88.</label>
      <mixed-citation publication-type="other">Steinbeck, C., Han, Y., Kuhn, S., Horlacher, O., Luttmann, E. &amp; Willighagen, E. The Chemistry Development Kit (CDK): An Open-Source Java Library for Chemo- and Bioinformatics. <italic>J. Chem. Inf. Comput. Sci.</italic><bold>43</bold>(2) 493–500 (2003).</mixed-citation>
    </ref>
    <ref id="CR89">
      <label>89.</label>
      <mixed-citation publication-type="other">Willighagen, E. L. <italic>et al.,</italic> The Chemistry Development Kit (CDK) v2. 0: atom typing, depiction, molecular formulas, and substructure searching. <italic>J. Cheminformatics</italic><bold>9</bold>(1), 1–19 (2017).</mixed-citation>
    </ref>
    <ref id="CR90">
      <label>90.</label>
      <mixed-citation publication-type="other">Hall, L. H., &amp; Kier, L. B. Electrotopological state indices for atom types: A novel combination of electronic, topological, and valence state information. <italic>J. Chem. Inf. Comput. Sci.</italic><bold>35</bold>(6), 1039–1045 (1995).</mixed-citation>
    </ref>
    <ref id="CR91">
      <label>91.</label>
      <mixed-citation publication-type="other">Klekota, J. &amp; Roth, F. P. Chemical substructures that enrich for biological activity. <italic>Bioinformatics, </italic><bold>24</bold>(21), 2518–2525 (2008).</mixed-citation>
    </ref>
    <ref id="CR92">
      <label>92.</label>
      <mixed-citation publication-type="other">Durant, J. L., Leland, B. A., Henry, D. R. &amp; Nourse, J. G. Reoptimization of MDL Keys for Use in Drug Discovery. <italic>J. Chem. Inf. Comput. Sci.</italic>, <bold>42</bold>(6), 1273–1280 (2002).</mixed-citation>
    </ref>
    <ref id="CR93">
      <label>93.</label>
      <mixed-citation publication-type="other">Kim, S. <italic>et al.</italic> PubChem Substance and Compound databases. <italic>Nucleic Acids Res, </italic><bold>44</bold>(D1), D1202–D1213 (2016).</mixed-citation>
    </ref>
    <ref id="CR94">
      <label>94.</label>
      <mixed-citation publication-type="other"> LAGGNER, C. SMARTS patterns for functional group classification (2005).</mixed-citation>
    </ref>
  </ref-list>
</back>
